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1.   INTRODUCTION 
Incidenceandsurvivalofrectalcancer
Colorectal cancer is one of the most common cancers in industrialized countries with an 
estimated incidence of more than 400 000 new cases annually in Europe (1). In Norway 
about 3500 new cases were registered in 2007, which makes colorectal cancer the second 
most common cancer in men and women after prostate and breast cancer (2). Rectal cancer 
constitutes approximately one-third of all colorectal cancers, and about 5% of all new cases 
of cancer diagnosed in Norway. Norway reports the highest incidence rate of colorectal 
cancer among the Scandinavian countries (3). Almost 80% of the patients are aged over 60 
years at diagnosis, and the incidence is about 50% higher in men than in women (2).  
Key risk factors associated with colorectal cancer are dietary factors (fibre, red meat, fish, 
calcium. etc.), physical exercise, obesity and alcohol (4-9). Most colorectal cancer cases are 
sporadic (75-85%) (8). Lynch syndrome and familial adenomatous polyposis (FAP) are well 
known, but rare, autosomal dominantly inherited conditions (10). Around 5-10% of colorectal 
cancers are associated with hereditary susceptibility.  
The mortality rates from rectal cancer have steadily decreased in Norway as well as in 
Europe and the USA, in particular over the last decades (11-13). According to the Norwegian 
Colorectal Cancer Registry, the 5-year survival rate has increased from 25% to over 60% in 
the period 1965-2007 (Figure 1) (11). 
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Figure1.Trendsinagestandardizedrelativesurvivalproportions,incidence,andmortalityrates(11).
 
The relative survival shows a pronounced decrease in the first years after diagnosis, but 
levels off after about 5 years (Figure 2). Patients surviving 6-8 years after diagnosis have a 
5-year relative survival probability of >90%, irrespective of age and sex (11). At the end of 
2007, there were 9250 people alive who had previously been diagnosed with anorectal 
cancer in Norway.  
 
 
Figure2.Longtermsurvivalbysex.
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Colorectal cancers most often originate in the mucosal glands and are classified as 
adenocarcinomas. There is no clear anatomical border between the sigmoid colon and the 
rectum; however, the rectum is usually defined as the bowel below the sacral promontory or 
within 15-17 cm from the anus, as measured by rigid rectoscopy. In the Norwegian Rectal 
Cancer Registry (NRCR), tumours up to 20 cm were registered as rectal cancers. Rectal 
cancers are classified according to the International Union Against Cancer (UICC) staging 
and the American Joint Commission of Cancer (AJCC) developed TNM classification of 
malignant tumours (Table I) (14, 15).  
 
Table1.TheUICCstagingsystemandTNMclassification
UICC staging system TNM classification 
T1-2 N0 M0
T1= tumour invades submucosa 
T2= tumour invades muscularis propria 
N0= no regional lymph node metastasis 
Stage I 
M0= no distant metastasis  
T3-4 N0 M0
T3= tumour invades through the muscularis propria into 
the serosa or the perirectal tissues 
T4= tumour directly invades other organs or structures 
and /or perforates visceral peritoneum 
N0= no regional lymph node metastasis 
Stage II 
M0= no distant metastasis  
Any T N1-2 M0
N1= metastasis to 1-3 regional lymph nodes  
N2= metastasis to 4 regional lymph nodes 
Stage III 
M0= no distant metastasis 
Any T any N M1Stage IV 
M1= distant metastasis 
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The probability of survival in rectal cancer is closely related to the pathological stage and the 
resection margins. Whereas patients with stage I disease have a 5-year survival rate of 79%, 
the survival rate is 64% in patients with stage II and 50% in those with stage III disease 
according to results from the Norwegian Colorectal Cancer Registry in the years 1993-2004 
(16). The circumferential resection margin (CRM) is important because involvement of this 
margin is associated with an increased risk of local recurrence and decreased survival in 
rectal cancer patients (17-19). 
Clinical staging of the rectal tumour is now performed using magnetic resonance imaging 
(MRI) and/or endorectal ultrasound (EUS). MRI is highly accurate in predicting CRM 
positivity, and assessing the depth of extramural spread, particularly in low rectal tumours 
(8). Preoperative assessment of the distance to the mesorectal fascia plays an important role 
in decision-making for preoperative (chemo-) radiotherapy, which is primarily given to reduce 
the risk of local failure. EUS is considered more accurate for assessing the depth of tumour 
growth into the bowel wall (in T1 and T2 tumours). There is still no reliable imaging technique 
to evaluate nodal disease preoperatively, because computed tomography (CT), MRI and 
EUS all rely on size criteria for predicting nodal metastases. The definitive TNM staging and 
evaluation of the distance to the CRM are performed at the pathological examination of the 
surgical specimen. 
Treatmentforrectalcancer
Surgery
Surgery is the mainstay in the treatment of rectal cancer. Over the past few decades, 
improvement in surgical techniques has led to significantly better prognosis for patients with 
rectal cancer. This progress started in the 1980s when anatomical dissection, termed “total 
mesorectal excision” (TME), was developed (20, 21).  With TME surgery the surgeon 
removes the tumour together with the surrounding mesorectal fatty tissue, including 
lymphatic and venous drainage. More exact surgery and surgery following the embryonic 
planes has resulted in increased local control with reduced rates of local recurrence and 
improved survival in rectal cancer (21-23). The TME technique has now become the 
standard surgical procedure in many countries, and was implemented in Norway during the 
1990s.  
Although TME is the recommended technique for tumour removal, there are three main 
surgical procedures for rectal cancer.  Anterior resection (AR) is the most widely used 
technique which re-establishes intestinal continuity and saves the anal sphincter. This 
operation is recommended when the tumour is situated in the mid- or upper part of the 
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rectum, or in low cancers, provided that a sufficient distal and circumferential tumour-free 
margin is attainable. However, in low cancers, where uninvolved resection margins are 
unattainable with an AR -technique (e.g. if the tumour extends into the pelvic floor), an 
“abdominoperineal resection” (APR) with amputation of the rectum and a permanent 
sigmoidostomy is performed. In selected patients, a resection of the rectum with closure of 
the distal part of the rectum and a permanent sigmoidostomy (the “Hartmann’s procedure”) 
may be preferred. 
 
TheNorwegianRectalCancerProject
Before 1993, the procedure for rectal cancer surgery was not standardized in Norway and 
varied among departments and surgeons. Some Norwegian surgeons had adopted the TME 
technique with good results (24). However, a national survey, including more than 700 cases, 
showed a local recurrence rate of 28% after curative rectal cancer resections with traditional 
surgery (25, 26), which was in sharp contrast to the 5% 5-year local recurrence rate reported 
after TME in an institution in England (27). On the initiative of dedicated surgeons, the 
Norwegian Rectal Cancer Project was established in 1993 to improve the surgical technique 
on a national level, aiming to introduce TME as a national standard for major rectal 
resections, and to reduce local recurrence rates and improve survival (23). In the first 4 years 
the proportion of patients undergoing TME increased from 78% to 92% (23). The frequency 
of 5-year local recurrence rate decreased from 15% in 1994 to 9% in 2004, and the total 5-
year survival rate increased from 60% to 69% in the same time period (16).
TheNorwegianRectalCancerRegistry
The Norwegian Rectal Cancer Registry (NRCR) was initiated by the Norwegian Rectal 
Cancer Project and is a part of the Cancer Registry of Norway, to which all cancers in 
Norway are reported. The NRCR was established in 1993 and the aim was to establish an 
instrument for continuous national quality control. Data on tumour characteristics, and 
primary treatment, and information about recurrences and metastases, are reported 
prospectively by the surgeons, and follow-up information is obtained by routine reminders 
sent to surgical departments. The histological assessment of the surgical specimen is 
extracted from each pathology department’s mandatory reports sent to the Cancer Registry. 
Information on dates of deaths is transferred from the Statistics Norway.  
At the latest update, 10 941 patients with rectal cancer had been registered in the NRCR. 
The data have been available as quality assurance for hospitals and the results on survival, 
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recurrence, treatment and diagnostics have been published in national reports as well as in 
international publications (16). In 2009, the registry expanded to include a national, 
prospective registration of all patients with colon cancer, and is now named the Norwegian 
Colorectal Cancer Registry.  
Radiotherapy
Historicaloverview
Before the mid-1980s, patients with rectal cancer usually underwent surgery alone, and the 
local recurrence rates were between 20 and 30% (25, 26, 28). Trials in the 1980s and 1990s 
showed a decrease in the risk of locoregional recurrence of approximately 50% with 
radiotherapy (RT) given preoperatively (25, 29, 30) or chemoradiotherapy (CRT) given 
postoperatively (26, 31-34), compared with traditional surgery alone. With the substantial 
decrease in local recurrence after the implementation of TME in the mid-1990s, it was 
questioned whether RT still had a role in the treatment of resectable rectal cancer (35, 36). 
However, in 2001 a large randomized Dutch trial observed a significant reduction in local 
recurrence 2 years after preoperative RT and TME compared with TME alone (37). After 5 
years of follow-up, local recurrence rates were significantly better with preoperative RT (6% 
versus 11%, respectively), but overall survival was not increased (38).    
Some countries have a preference for giving RT preoperatively, and others have given CRT 
postoperatively in primarily resectable tumours. The main advantage of postoperative CRT is 
that it allows accurate pathological staging and thereby restricts adjuvant treatment to high-
risk patients without metastases (39). However, recent randomized controlled trials have 
shown that preoperative RT is more effective and gives fewer side effects than postoperative 
CRT (40-42). Furthermore, improvements in preoperative imaging have proven more 
accurate in identifying patients at risk (43). Nevertheless, the indications for RT are still 
debated (44).  
Another ongoing debate has been on the fractionation schedule in curative RT for high-risk 
patients (45). Sweden and the Netherlands have developed a schedule with 25 Gy given in 
five fractions, arguing that “short-course radiotherapy” has a greater dose efficacy, gives less 
proliferation of subclinical tumour cells, less acute toxicity, better patient compliance and 
finally is more convenient than a 5-week schedule (46). Furthermore, the Swedish Rectal 
Cancer Trial has showed improved survival with preoperative RT (30, 47). However, from a 
radiobiological perspective there has been concern about the late effects with short-course 
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RT as large fractions are known to increase late morbidity (48). Apart from a Polish study 
with only 1 year of follow-up, no reports from randomized trials on this subject have so far 
been published (49). An ongoing study (the Stockholm III study) will address these issues. 
RT with “conventional fractionation” of 2 Gy, to a total of 46-50 Gy in 5 weeks, often 
combined with 5-fluorouracil (5-FU)-based chemotherapy, is currently the standard 
preoperative treatment for primarily non-resectable cancers in most countries. Several 
randomized trials and a recent Cochrane review have concluded that preoperative CRT is 
more effective than preoperative radiotherapy alone, with only a moderate increase in acute 
toxicity (50-53). Preoperative CRT aims to induce tumour shrinkage and facilitate radical 
surgery. However, there is no evidence that CRT influences sphincter preservation (54). At 
present, newer drugs such as irinotecan and oxaliplatin, as well as targeted drugs, are being 
investigated, but the results on tumour control, survival and toxicity are not conclusive for the 
time being (55-57).  
RadiotherapyTreatmentforrectalcancerinNorway
According to Norwegian guidelines, preoperative CRT is recommended when preoperative 
MRI reveals a distance from tumour (or tumour-infiltrated lymph node) to the mesorectal 
fascia of 3 mm, and for all T4 and /or tethered tumours (58). The concomitant 
chemotherapy may be given as oral treatment with capecitabine 5 days a week during RT 
treatment, or as bolus 5-FU and folinate according to the Nordic FLv regimen (on days 1, 2, 
11, 12, 21, and 22 of RT). Postoperative CRT is indicated in non-radically resected tumours, 
if CRM <2 mm, or after perioperative perforation of the tumour or adjacent bowel if treatment 
was not given preoperatively. In Norway, rectal cancer is usually treated with fractions of 2.0 
Gy, 5 days a week for 5 weeks to a total dose of 50 Gy to the gross tumour area and 46 Gy 
to the area at risk.  
Before the late 1990s, the RT treatment was based on two-dimensional simulation of 
standard fields using bony landmarks: the cranial field border at the L5-S1 interspace, the 
lower border close below the anal verge or 3 cm above for higher tumours, and the lateral 
border close to linea terminalis. After the introduction of technical advances in treatment 
planning around the year 2000, an increasing proportion of patients had CT-based three-
dimensional (3D) treatment planning (Figure 3). This may result in improved coverage of the 
clinical target volume (CTV) and the possibility of avoiding or shielding normal tissue. CT-
based treatment planning is now considered mandatory in all RT departments in Norway. 
The guidelines for delineation of the CTV are based on clinical knowledge of the predominant 
location of local recurrences and the distribution of lymphatic spread in rectal cancer (58-60).  
14

 
 
 
Figure3.ThedosedistributioninRTtreatmentforrectalcancerwithoneposterioranteriorandtwo
lateralfields.
Along with the improved local control after preoperative RT, and the advances in 
preoperative MRI, there has been an increase in the use of preoperative RT in Norway; from 
8.5% in the years 1998-2001, to 20.2% in 2004, and a decrease in the use of postoperative 
RT from 13.6% to 3.6% in the same period (16, 61). Today the rate of preoperative RT has 
reached about 30% (Kjell Magne Tveit, personal communication). 
 
Multidisciplinaryteamdiscussions
Advances in MRI has enabled the identification of prognostic factors that are helpful in 
selecting patients who may benefit from multimodality treatment (43, 62). The national 
guidelines in Norway have recommended that newly diagnosed patients are discussed in 
multidisciplinary teams, consisting of specialist surgeons, oncologists, radiologists and 
pathologists. The aim of the multidisciplinary team discussions has been to select the best 
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treatment for the patients, and hence to reduce the frequency of local recurrence and 
improve the survival of rectal cancer patients (63, 64).  
 
Normaltissuesideeffectsfromradiotherapy
Therapeutic radiotherapy consists of ionizing radiation, most often electromagnetic radiation, 
or photons. Ionizing radiation may lead to breaking of chemical bonds, with damage in 
cellular DNA, either directly or indirectly through free reactive oxygen. The cell then activates 
a DNA damage response, including several interrelated signalling pathways. The DNA 
damage sensors recognize DNA damage and may activate three important effect pathways: 
cell-cycle checkpoints, programmed cell death or DNA repair. In comparison to normal tissue 
cells, tumour cells have reduced capacity to repair radiation-induced DNA damage (48). 
Although radiotherapy primarily affects tissues in the vicinity of the target volume, normal 
tissue in the beam’s path may receive radiation. All tissues will respond to the radiation 
doses at the molecular, histological or clinical level. However, the probability of developing 
toxicity depends on several factors: physical factors (e.g. dose, dose per fraction, volume), 
patient-related factors (e.g. diabetes, hypertension and smoking), genetic factors and other 
treatment (e.g. prior surgery or concurrent chemotherapy). Hence, not all patients exhibit 
symptoms or clinical manifestations to the same degree.  
Normal tissue effects have been classified according to the time of onset of the clinical 
symptoms (48). Early (acute) side effects are observed during, or shortly after, radiotherapy. 
These side effects are usually transient and therefore considered less important for limiting 
treatment dose. Early effects are seen in tissues with rapid cell proliferation, such as 
intestinal epithelium, skin and bone marrow. On the other hand, late (chronic) side effects 
become manifest after a latency of months to many years. They are usually irreversible and 
often progressive, and appear in tissues with a slower turnover of cells such as 
subcutaneous tissue, brain, kidney, liver and the intestinal wall. The probability of late tissue 
morbidity is dose limiting in RT.  
In the acute side effects from radiotherapy, the symptoms are based on radiation-induced 
impairment of cell reproduction (48). The consequence is progressive cell depletion, which is 
regularly accompanied by inflammatory changes. Late normal tissue effects are based on 
complex pathophysiological processes that involve radiation-induced changes in 
parenchymal cells (cell death), fibroblasts (differentiation), vascular endothelial cells (loss of 
capillaries) and macrophages (48). These cells interact through activation of cytokines and 
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growth factors, resulting in progressive parenchymal damage, which may lead to loss of 
function within the irradiated volume. In general, there is little relation between the 
expression of early and late normal tissue side effects. However, so-called “consequential 
late effects” may occur when the early reacting tissue compartments (e.g. epithelia) have a 
protective function against mechanical and/or chemical exposure (65). 
 
Latemorbidityafterpelvicradiotherapy
Pelvic radiation is used to treat gynaecological, genitourinary and gastrointestinal tumours. 
Organs at risk in pelvic radiation include the gastrointestinal tract (small bowel, colon, rectum 
and anus), bone and bone marrow, urinary tract (bladder, urethra and ureter), the sexual 
organs (vulva, vagina, uterus, ovaries, testicles, prostate gland and penis) and the skin. 
Thegastrointestinaltract
The small bowel is the organ most often affected by pelvic radiation (66). Gastrointestinal 
symptoms are more frequent after RT for gynaecological and gastrointestinal cancer 
compared with RT for urological cancer (67). Symptoms of delayed bowel toxicity usually 
present after a latency period of between 6 months and 3 years (68). Progressive intestinal 
wall fibrosis may cause strictures and obstruction, and localized areas with ischaemic 
necrosis may give rise to fistulas or bowel perforation (68). Radiation-induced chronic 
diarrhoea is thought to increase proportional to the radiation dose and the irradiated volume 
(69). Radiation enteropathy of the terminal ileum may be clinically characterized by 
cobalamin deficiency or subnormal serum-calcium values (70, 71). In patients with severe 
mucosal injury, chronic ulcers and fibrosis, clinically manifesting as rectal pain, bleeding, 
tenesmus and faecal urgency, may occur. Histological analyses of the irradiated anal 
sphincter have revealed time-dependent damage to the myenteric plexus of the internal anal 
sphincter (72). Clinical studies have suggested that radiation-induced dysfunction of the 
internal anal sphincter, reduction in rectal compliance and volume and heightened rectal 
sensitivity may contribute to faecal urgency and incontinence (73, 74).  
The most frequent symptoms documented in long-term follow-up of patients treated with RT 
for rectal cancer are frequent bowel movements, faecal incontinence for loose and solid 
stools and rectal emptying problems (in about 20-60% of patients) (49, 75-77).  
Theurinarytract
Late sequelae of the urinary tract include persistent dysuria, contracted bladder, 
vesicovaginal fistulas and haematuria. Median onset of late urinary side effects is 13-20 
17

months, but latency times can range up to 10 years (48, 78). Morphologically, the initial 
phase is characterized by progressive mucosal breakdown, ranging from superficial 
denudation to ulceration (48). The urothelial changes are accompanied by areas of 
compensatory hyperproliferation and secondary fibrosis of the bladder wall or the urethral 
sphincters. Telangiectasia can result in severe bleeding episodes. 
Radiation effects on the bladder have been described after treatment for among others 
cervical cancer, prostate cancer and bladder cancer (78-81). However, because the disease 
itself might have impaired the bladder function, separating radiation effects from the disease 
may be difficult. In studies of rectal cancer, an increased prevalence of urinary incontinence 
after RT has been described in some studies (82). However, in a multivariate analysis of 
more than 700 patients treated with or without preoperative RT and TME, the authors 
concluded that urinary dysfunction is not related to RT, but rather to surgical nerve damage 
(83). 
Gonads
The testes are normally outside the radiation field, but because of the proximity to the target 
volume they may receive scattered radiation. It is known that scattered radiation during pelvic 
RT may affect testicular function, the seminiferous tubules are particularly radiosensitive and 
total doses of 1.5-2.0 Gy may lead to permanent infertility (84). The effect of radiation on 
Leydig cell function is less documented; however, there appears to be a dose-response 
effect (85, 86). Leydig cells account for 75% of the total testosterone production in the normal 
adult male. Low levels of testosterone may result in decreased libido and sexual dysfunction, 
increased risk of premature osteoporosis, and changes in body composition and personality 
(87-89). In a previous study, Dueland et al. measured a mean cumulative dose to the 
testicles of 8.4 Gy along with a 25% decrease in serum testosterone (S-testosterone) levels 
4-6 weeks after RT for rectal cancer (90). Another study found similar results in a group of 11 
men (91). At the time of the current study no data after long-term follow-up of patients treated 
with RT for rectal cancer were available. 
Radiation to the ovaries may cause permanent menopause after a total exposure of 4-7 Gy 
in women aged from about 40 years and older (92). In pelvic RT for rectal cancer, the ovaries 
are in the radiation field, and in premenopausal women radiation-induced ovarian failure is 
inevitable.  
Sexualfunction
Pelvic RT can lead to sexual dysfunction in men and women. In men most reports focus on 
erectile dysfunction, although decreased libido, lack of ejaculation, haematospermia, pain at 
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orgasm and alteration in the intensity of orgasm have also been described (93-95). The 
aetiology of erectile dysfunction after pelvic RT is not fully understood, but possible 
mechanisms include neural injury, vascular alterations and penile corporal structural changes 
(96). The co-existence of vascular risk factors such as diabetes mellitus, hypertension and 
smoking may predispose a patient to develop side effects from RT (95, 96).  
In men treated with RT for prostate cancer, erectile dysfunction is a well-known sequela and 
reported in up to 70% of patients (97). In rectal cancer patients, a few studies have reported 
a higher frequency of erectile dysfunction and ejaculation problems, as well as reduced 
sexual activity, in patients treated with RT (98-100). 
Sexual function in women following RT has been poorly evaluated. Most studies have been 
conducted in patients with gynaecological cancer, focusing on problems such as vaginal 
stenosis, dyspareunia, bleeding and lubrication changes (101). Others have also reported 
lack of sexual interest and dissatisfaction with sex life (102). RT-induced vaginal fibrosis and 
atrophy may give rise to adhesions and vaginal stenosis, telangiectasia or thinning of the 
mucosa (94). Serious complications include mucosal necrosis and fistula formation. The data 
on sexual dysfunction in women treated with RT for rectal cancer are scarce. In one large 
randomized trial, RT had a negative impact on female sexual activity and sexual function (98, 
103); another smaller study found an increased risk of dyspareunia (104). Furthermore, the 
effect of RT on female sexual function has been only briefly assessed in small subgroup 
analyses (105-107).
Otherlatesideeffects
Preoperative RT significantly increased the risk of venous thromboembolic disease, femoral 
neck and pelvic fractures in the initial controls of the Stockholm I and II studies (82). 
However, these findings were not confirmed in the long-term follow-up (108) or in the Dutch 
TME trial (77). Recently, a prospective American study found a 3-year actuarial rate of sacral 
insufficiency fractures of 3% after preoperative CRT for rectal cancer (109). About half the 
patients had symptoms requiring pain medications. An increased risk of cardiovascular 
disease in the RT group has been observed (108). Furthermore, irradiated patients, 14 years 
after treatment, have a more than doubled risk of developing second cancers compared with 
controls treated with surgery only (9.5% vs. 4.3%, respectively) (110).  
Healthrelatedqualityoflife
Health-related quality of life (QoL) is defined as a multidimensional measure, comprising 
physical, mental and social elements, and symptoms related to the disease and treatment 
(111). It is considered a subjective measure and is consequently most reliable when reported 
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from the patients themselves. As long-term survival in cancer patients improves, the focus on 
treatment effects on QoL has increased. However, knowledge about QoL and the impact of 
treatment-related side effects in long-term survivors after RT for rectal cancer is scarce and 
mainly based on studies on patients treated with preoperative short-course RT (5 Gy x 5) 
(66). A Swedish study with 9-21 years of follow-up found that patients who had received 
preoperative RT scored significantly lower for social functioning and, furthermore, that 
patients with faecal incontinence had significantly lower QoL scores than those who were 
continent (82, 112). In a study of 142 patients treated with RT for gynaecological, urological 
or gastrointestinal tumours, about 50% suffered from bowel problems affecting their QoL 3 
months or more after RT (67). On the other hand, a large randomized trial found no 
difference in QoL scores 2 years after treatment with or without preoperative RT for 
resectable cancer (98).  
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2.   AIMS OF THE STUDY 

The aim of the study was to evaluate the effect of RT on long-term functional outcome and 
quality of life in rectal cancer patients. Patients treated with RT and surgery (RT+) were 
compared with patients treated with surgery alone (RT-). The main hypothesis was that 
patients treated with RT had a worse functional outcome, and that a poor functional outcome 
had a negative impact on quality of life. 
 
The following were the specific aims: 
 To examine whether RT+ patients had more bowel, anorectal and bladder 
dysfunction compared with RT- patients.  
 To examine whether RT+ patients had impaired QoL compared with RT- patients and 
also compared with the Norwegian general population, and whether a worse 
functional outcome affected QoL. 
 To examine whether S-testosterone was reduced in male RT+ patients compared 
with male RT- patients, and whether hormonal status was associated with radiation-
related factors. 
 To examine whether RT+ patients had significantly impaired sexual function 
compared with RT- patients. 
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3.   MATERIALS AND METHODS 
Studypopulation,designanddatacollection
Patients were sampled from a national database, the NRCR, which is part of the Cancer 
Registry of Norway, and includes all patients with rectal cancer in Norway diagnosed since 
November 1993 (23).  
We identified all patients in the NRCR diagnosed with primary rectal cancer from November 
1993 to December 2003 who had been treated with pre- or postoperative (chemo-) RT with 
curative intention and who were registered without metastasis, local recurrence or 
synchronous prostate cancer (RT+ patients). Only patients still alive at least 2 years after 
surgery were included. To serve as controls, patients treated with surgery alone (RT- 
patients) were sampled from the NRCR using the same criteria as the RT+ patients. The 
controls were drawn randomly and were not matched for age-, treatment- or disease-related 
factors, in order to allow analyses of the effect of these variables.  Instead of matching 
patients to be included, potential confounding factors were adjusted for in multivariable 
statistical analyses.  
Sample size estimation was based on QoL (measured with QLQ C-30). A difference in mean 
score of 10 points is considered clinically significant (113). Based on data from a previous 
Norwegian study of QoL in rectal cancer patients (114), we assumed a standard deviation of 
SD=26. With a power of 80% and a two-sided significance level of 5%, we estimated that at 
least 108 patients from each treatment group (RT+ and RT-) had to be included (114). For 
the LENT SOMA and sexual function data we had little prior knowledge about the distribution 
of the scores and sample size could not easily be calculated. As we planned to perform 
analyses on subsets of the data, we decided to include all RT+ patients available. Twice as 
many RT- patients were identified in order to increase the power of the study. 
The patients were contacted by mail and invited to participate in the study. Two reminders 
were sent to non-responders after approximately 2 and 4 weeks. Patients who returned 
written informed consent participated in a structured questionnaire-based telephone 
interview, and they completed two self-administered questionnaires: the EORTC QLQ-C30 
(all patients) and the IIEF (males) or the SVQ (females), and returned them by mail. Blood 
samples were drawn at the patients’ general practitioner’s office.  
A flow chart of the inclusion process is presented on page 23. Patients were excluded if they 
had undergone surgery with local excision, or if they had died, moved abroad or were not 
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able to give informed consent due to dementia or severe illness. Furthermore, patients were 
excluded from the analyses if the telephone interview disclosed that they: (1) had local 
recurrence or current metastases at the time of the study and (2) had received pelvic RT for 
other malignancies. Other exclusion criteria specific for each of the papers I-IV were as given 
below.  
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Paper I 
Patients were excluded from the analyses if the RT charts disclosed that they had received a 
total dose of <42 Gy (less than 90% of planned dose).  
Paper II 
Patients were excluded from the analyses if the telephone interview disclosed current or 
previous treatment for prostate or testicular cancer.  
Paper III 
Patients were excluded from the analysis if they were aged 80 years, or if the telephone 
interview disclosed current or previous treatment for prostate or testicular cancer. 
Paper IV 
Patients were excluded from the analysis if they were aged 80 years. 
Ethical considerations 
All participating patients signed an informed consent form. The study was approved by the 
regional committee for Medical Research Ethics and the Norwegian Data Inspectorate. 
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FLOWCHARTOFTHESTUDYPOPULATIONINPAPERSIIV

IdentifiedfromtheNRCR:
N=1160
Eligible:N=1019
(468femalesand551males)
ParticipantspaperIV: 
N=172(52%)
Eligiblefemales
paperIV:
N=332
ExcludedinpaperIV
>80yearsold:N=136

ParticipantspaperIII: 
N=241(59%)
Eligiblemales
paperIII:
N=409
ExcludedinpaperIII
>80yearsold:N=141
Prostate/testicularcancer:
N=1
ParticipantspaperII: 
N=290(53%)
Eligiblemales
paperII:
N=546
ExcludedinpaperII 
Prostate/testicularcancer:
N=5
ParticipantspaperI: 
N=535(53%)
EligiblepaperI:
N=1012
ExcludedinpaperI 
<42Gy:N=7

Metastasis/recurrence/
otherpelvicRT:N=11
Localexcision/noexcision:
N=71
Dead/moved/unableto
consent:N=59
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Theinterview
Symptoms of late toxicity on bowel, anorectal and bladder function were assessed using the 
LENT SOMA scoring system (115) and the St Mark’s score  of incontinence (116) in a 
questionnaire-based, structured, telephone interview (see Appendix A). The interview also 
contained additional questions such as current medication, comorbidity, working status and 
smoking. The interview was pilot tested in 10 patients with rectal cancer to evaluate the 
feasibility of the interview before the study. The patient interviews were performed by a 
research-nurse or physician.  
 
TheLENTSOMA  
The LENT SOMA is an international instrument for recording late radiation effects on normal 
tissue, published in 1995 by the European Organization for Research and Treatment of 
Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG) (115). The instrument 
consists of four separate elements comprising subjective (patients’ symptoms), objective 
(clinical examination), management (medical intervention) and analytical (objective 
assessment) data for all anatomical sites. In this study the questions were designed to 
answer the “subjective” and “management” part for the small intestine/colon, rectum and 
bladder/urethra.
The LENT SOMA scoring system was designed to record side effects in detail and pays 
attention to both the frequency and the severity of late effects. The LENT SOMA scales have 
not been fully validated, but have been compared with other scoring systems, such as the 
RTOG/EORTC late effects scoring system, and the Franco-Italian scale. It was found to be 
feasible for use in a clinical setting and to provide additional information on subjective 
treatment effects (117-120). The initial recommendation, to sum all scores for each organ 
and divide the result by the number of questions, was withdrawn because this method may 
underestimate the severity of some side effects (121). We therefore analysed the questions 
separately and reported the frequency of patients with a specific symptom. 
StMark’sscoreofincontinence
The degree of faecal incontinence was assessed in the telephone interview with S. Mark’s 
score (Table 2). St Mark’s score of incontinence has been validated and shown to be 
reliable, sensitive and applicable to oncological patients treated with pelvic RT (67, 116, 
122). The questionnaire contains seven questions about type (gas, fluid or solid) and 
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frequency of faecal incontinence, and alteration in lifestyle, scored on a 0- to 4-point Likert 
scale. Furthermore, it contains questions about the need to wear sanitary pads, use of 
antidiarrhoeal medication and faecal urgency. The calculated incontinence score ranges from 
0 (complete continence) to 24 (complete incontinence), with the time frame being the last 4 
weeks. To determine the association between RT and faecal incontinence after adjusting for 
potential confounding factors, we dichotomized the symptom scores into whether or not it 
happened more frequently than once a month.   
 
Table2.StMark’sscoreoffaecalincontinence 
 Never Rarely Sometimes Weekly Daily
Incontinenceforsolidstool 0 1 2 3 4
Incontinenceforliquidstool 0 1 2 3 4
Incontinenceforgas 0 1 2 3 4
Alterationinlifestyle 0 1 2 3 4
    No Yes
Needtowearapadorplug    0 2
Takingconstipationmedicines    0 2
Lackofabilitytodeferdefecationfor15minutes    0 4
Never=noepisodesinthepastfourweeks;Rarely=1episodeinthepastfourweeks;Sometimes=>1episodeinthepast
fourweeksbut<1perweek;Weekly=1ormoreepisodesaweekbut<1perday;Daily=1ormoreepisodesaday.Addone
scorefromeachrow:minimumscore=0perfectcontinence;maximumscore24=totallyincontinent
 
 
Thebloodsamples
Testosteroneandgonadotrophins
Male patients who agreed to participate in the study (both RT+ and RT-) received a 
laboratory requisition, tubes for blood sampling and a letter with information about the 
procedure. The samples were drawn at the general practitioner’s office or at the local 
hospital before 10am and were sent to the Hormone Laboratory at Aker University Hospital, 
Oslo, Norway for analysis. The tests were analysed and the results reported consecutively.  
Serum-testosterone was analysed by radioimmunoassay. Serum sex hormone-binding 
globulin (SHBG), follicle-stimulating hormone (FSH) and luteinizing hormone (LH) were 
measured by immunofluorometric assay. Free testosterone values were calculated from total 
testosterone and SHBG, using a fixed albumin level according to Vermeulen et al. (123). 
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Low S-testosterone was defined as S-testosterone below the reference range (<8 nmol/L). 
The laboratory’s reference values for FSH and LH were <12 IU/L and for SHBG 15-90 nmol/l. 
No reference values had been established for calculated free testosterone.  
The patients’ weight and height were self-reported, and the body mass index (BMI) was 
calculated (weight/ height x height).
Thequestionnaires
TheQLQC30(seeappendixB)
The QoL was assessed by a self-administered questionnaire, the EORTC QLQ-C30 version 
3.0 (124). The QLQ-C30 was developed to assess QoL in cancer patients and has been 
validated and tested in different cultures and in various cancer populations (124, 125). The 
questionnaire includes 30 questions (items) forming five functional scales (physical, role, 
emotional, cognitive and social), three symptom scales (fatigue, nausea and vomiting, and 
pain) and a global health status/QoL scale. Furthermore, it contains six single items 
(dyspnoea, insomnia, appetite loss, constipation, diarrhoea and financial difficulties). The 
time frame used is the past week. 
The questions constituting the global QoL scale are scored on a modified visual analogue 
scale from 1 to 7. The remaining 28 questions have four response categories: “not at all”, “a 
little”, “quite a bit” or “very much”. All calculations on the QLQ-C30 data were performed after 
linear transformation of the scores to a scale from 0 to 100. A high score on the functional 
scales indicates better functioning, whereas a high score on the symptom scales or single 
items indicates more symptoms. Missing values were handled as recommended by the 
EORTC Quality of Life Group (126). If at least half the items from the scale had been 
answered, the missing item was assumed to have values equal to the average of those items 
present. If less than half of items from the scale had been answered, the scale score was 
said to be missing. Of the 491 QLQ-C30 questionnaires returned in this study, the mean 
proportion of missing items was only 0.5% (range 0-1.8%). 
In the current study we assessed only the function scales from QLQ-C30, because the 
potential late effects from RT on gastrointestinal and bladder function were covered in depth 
in the LENT SOMA and St Mark’s Incontinence Scale. For the same reasons we did not use 
the QLQ CR-29, which is the colorectal module recommended as supplementary to the QLQ-
C30. The function scale scores for RT+ patients were compared with the scores for the RT- 
patients, and with those from an age- and gender-adjusted sample of the Norwegian general 
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population (127). A difference in mean score of 10 was considered clinically significant, 
based on a study by Osoba et al., in which a change in mean score of 5-10 was interpreted 
as “little”, 10-20 as “moderate”, and >20 as “very much” (113).  

MalesexualfunctiontheIIEF(seeappendixC)
Male patients were asked to complete the International Index of Erectile Function (IIEF), a 
questionnaire shown to have good psychometric properties (128, 129), and that has been 
widely used to evaluate erectile function in patients with pelvic cancer (130). The 
questionnaire was translated into Norwegian following a standard linguistic validation 
process (131).  
The IIEF is a 15-item questionnaire where the responses are scored on a 5- or 6-point Likert 
scale, with lower scores indicating poorer sexual function. The time frame used is the last 4 
weeks. The items are grouped into five domains: sexual desire, erectile function, orgasmic 
function, intercourse satisfaction and overall satisfaction with sex life. For each domain a 
summary score is calculated. Any missing response results in the patient being omitted from 
the final calculation of the domain score, according to the IIEF scoring manual. The erectile 
function (EF) score has been ranked into 5 levels according to clinical severity (129, 132). 
When analysing the associations between RT, patient- and treatment-related characteristics, 
and EF, the EF score was dichotomized into no/mild ED or moderate-to-severe ED. 
Questions about treatment for ED and ejaculation problems (dry ejaculation) were added. 
The single question about ejaculation problems was later omitted from the analyses due to a 
high number of missing responses.
FemalesexualfunctiontheSVQ(seeappendixD)
At the time of the study, there was no comprehensive questionnaire available that assessed 
sexual function in women with rectal cancer. The Sexual Function and Vaginal Changes 
Questionnaire (SVQ) has been designed to assess sexual function and vaginal changes in 
gynaecological cancer patients treated with surgery and/or RT, and has been tested to 
establish reliability and validity (133).  As we aimed to use a questionnaire that covered 
vaginal problems often observed after pelvic RT, this questionnaire was considered an 
appropriate choice. The Danish version of the SVQ was obtained from the author of the 
original validation study (133). A forward-backward translation was performed, and the 
interpretation of the final version was pilot tested in 10 female patients with rectal cancer 
undergoing treatment at our department. 
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The SVQ is a 17-item questionnaire that consists of two parts; the first is answered by all 
respondents and concerns intimacy, sexual interest, satisfaction with sex life/lack of sex life 
and worries about sex life. The second part is answered only by women who have been 
sexually active during the last month and includes symptom scales on vaginal changes (VC) 
and a scale on sexual functioning (SF). The responses are scored into four categories (“not 
at all”, “a little”, “quite a bit” and “very much”) that are transformed into a 1-4 scale. Two 
questions are scored on a Likert scale, ranging from 1- to 7. A higher score on a symptom- 
scale represents more symptoms and a higher score on a function scale represents better 
functioning. Missing values were replaced using the same methods as in the QLQ-C30 (126, 
134). Logistic regression analyses were performed to adjust for potentially confounding 
factors. For these analyses the answers were dichotomized into “quite a bit/very much” or 
“not at all/a little”. Questions about use of systemic or topical oestrogens or vaginal lubricants 
were added. 
Statisticalanalyses
Most sets of continuous data in this thesis were of non-normal distribution, and the results 
and measures of variation were given as median (range) values. Comparisons between RT+ 
and RT- patients were done with the Mann-Whitney U-test for two independent samples. 
Differences in proportions between the two treatment groups were analysed using Pearson’s 
chi-square and the chi-square test for linear trend if data were ordinal. All tests were two 
tailed, and a p value <0.05 was considered statistically significant. 
In paper I, mean scores of QoL were presented although the data were not from a true 
continuous scale. The QoL- scores were linearly transformed into scales ranging from 0 to 
100 based on two to five questions with four answer categories (none at all- a little- quite a 
bit- very much). With few response categories and a high proportion scoring 0 (no 
symptoms) or 100 (no dysfunction), the medians are rather uninformative. Due to obviously 
skewed distributions non-parametric tests (Mann-Whitney U test) were used for comparison 
between groups of patients. 
Spearman’s rank order correlation (rho) was calculated to assess the relationship between 
the frequency of incontinence and the scores for global QoL perception and social function, 
because a linear relationship was not expected between the variables. 
Multiple logistic regression analysis was applied to evaluate associations between RT details 
and patient-reported symptoms such as faecal incontinence and urinary incontinence in 
paper I, erectile dysfunction in paper III and vaginal problems in paper IV. Symptoms were 
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dichotomized according to severity and/or frequency. The strength of the association was 
expressed as odds ratios (ORs) with 95% confidence intervals (CI). Potentially confounding 
factors were identified by searching the literature and from biological considerations, and 
included in the analyses with multiple explanatory variables if they were statistically 
significant (p <0.05) in separate logistic regression analyses with one explanatory variable. 
Generally, we avoided including a large number of covariates in the regression model and 
applied the rule of thumb that the number of covariates should not exceed 10-15% of the 
number of events (135). Due to the low number of sexually active females, fewer covariates 
could be used simultaneously in paper IV than in papers I-III, and the models were built by 
repeatedly applying separate sets of covariates and excluding those that were a long way 
from being statistically significant.  
In paper II, the relationship between testosterone and gonadotrophins and RT was examined 
with multiple linear regression analyses. Potentially confounding factors were identified from 
a literature search and biological plausibility. The variables included in the final regression 
models were restricted to statistically significant covariates (p <0.05) only. 
Except for the confirmatory factor analysis of the IIEF, all statistical analyses were done with 
the latest version of the Statistical Package for Social Sciences (SPSS, Inc, Chicago, IL).  
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4.   SUMMARY OF RESULTS 
PaperI
The aims of this study were to compare patient-reported bowel, anorectal, and urinary 
function in RT+ and RT- patients, and to assess if anorectal or bladder dysfunction had a 
negative impact on social function and global quality of life and health perception (global 
QoL). The data on late morbidity were collected by a telephone interview, with emphasis on 
bowel, rectal, sphincter and urinary function. For assessment of QoL, the patients completed 
a self-administered questionnaire, the EORTC QLQ-C30, and returned it by mail. A total of 
535 eligible patients were interviewed, after a median time since surgery of 4.8 years.  
 
Bowel and bladder-function 
RT+ patients (n = 199) had increased bowel frequency compared with RT- patients (n = 336); 
19% vs 6% had more than eight daily bowel movements (LENT SOMA grade 3-4) (p
<0.001). In patients without a stoma, a higher proportion of RT+ (n = 69) compared with RT- 
patients (n = 240), were incontinent for loose stools (49% vs 15%, p <0.001), needed pad 
(52% vs 13%, p <0.001), or lacked ability to defer defecation (44% vs 16%, p <0.001). After 
adjusting for tumor distance from the anal verge, the odds of symptoms of faecal 
incontinence in RT+ patients was still three to seven times higher than in RT- patients, and 
the mean incontinence score was significantly higher in RT+ than in RT- patients (9.2 vs 3.9, 
p <0.001).  In patients without a stoma, a higher proportion of RT+ compared with RT- 
patients had loose or liquid stool (36% vs 16%, respectively, p <0.001). There were no 
statistically significant differences in the proportion of RT+ vs. RT- patients reporting rectal 
pain (13% vs. 6%, respectively, p = 0.06) or blood in the stools (9% vs 6%, respectively, p = 
0.27) over the last month.  
 
Urinary incontinence was more common in RT+ than in RT- patients (36% vs 24%, p = 0.02). 
Daily urinary incontinence (LENT SOMA grade 3) was less frequent, but occurred more often 
after RT (9% in RT+ vs 2% in RT-, p = 0.001). There was no association between urinary 
incontinence and ypT- stage or tumour height above anal verge, or type of resection 
(AR/APR). There were no significant differences in voiding frequency, haematuria or dysuria 
between the two treatment groups. 
 
Quality of life 
In the interview, 15% of the RT+ patients without stoma, compared with 4% of the RT- 
patients, answered that their bowel function resulted in major restrictions in their social life (p
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= 0.003). According to the QLQ- C30 data, RT+ patients had significantly impaired social 
function compared to the RT- patients (mean 70 vs 82, p <0.001), as well as compared with 
age- and sex-adjusted values from the Norwegian general population. There were no 
differences in the remaining function scales.  
 
Patients who suffered from faecal incontinence weekly or more often had significantly 
impaired scores for social function and global QoL compared with continent patients. Also, 
patients with reduced ability to defer defecation, or patients using constipating medication, 
had significantly lower mean scores for social function and global QoL. The impairments in 
mean scores were between 10- and 20 points, a clinically moderate difference. Urinary 
incontinence of any grade did not affect QoL- scores, but the small subgroup of patients with 
daily episodes had significantly lower scores for several function scales. 
Conclusions: RT for rectal cancer is associated with considerable long-term effects on 
anorectal function, especially in terms of increased bowel frequency and increased risk of 
faecal incontinence. RT+ patients reported lower scores for social function, and faecal 
incontinence had a negative impact on QoL. 
PaperII
The aims of the study were to examine whether RT for rectal cancer was associated with 
reduced S-testosterone and whether male hormonal status was associated with RT 
treatment-related factors. Blood tests were received from 290 men, 116 RT+ and 174 RT- 
patients, and the median age was 66 years and 71 years, respectively.  
 
In the RT+ group, 27% of patients had S-testosterone levels below the reference range (8–
35 nmol/L), compared with 10% of the RT- patients (p <0.001). RT+ patients had lower S-
testosterone (mean 11.1 vs 13.4 nmol/L, p <0.001) and lower calculated free testosterone 
(mean 214 vs 235 pmol/L, p <0.05) than RT- patients. When adjusting for age and BMI, the 
mean S-testosterone level among RT+ men was 2.7 nmol/l (95% CI= -1.5 to -3.9), lower than 
in RT- men, a reduction of 20%. Serum FSH was three times higher in the RT+ group than in 
the RT- group (median 18.8 vs 6.3 IU/L, p <0.001) and serum LH was 1.7 times higher 
(median 7.5 vs 4.5 IU/l, p <0.001).  
 
The levels of total S-testosterone, calculated free testosterone and gonadotrophins were 
related to the distance from the bony pelvic structures to the caudal field edge. Multiple 
regression analysis showed a significant association between lower caudal field edge and 
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lower S-testosterone, signifying that the proximity of the testicles to the radiation field impacts 
on testosterone levels. Treatment with two-field technique was significantly associated with 
reduced S-testosterone levels compared with three fields or more. 
 
Conclusions: Increased serum levels of gonadotropins and subnormal serum levels of 
testosterone indicate that curative RT for rectal cancer can result in permanent testicular 
dysfunction.  
PaperIII
The primary aim of this study was to compare self-rated sexual functioning, in male patients 
who had surgery for rectal cancer and either RT or no RT, using an instrument with 
established psychometric properties, at least 2 years after surgery. As we had previously 
shown that RT for rectal cancer can lead to permanent reduction in S-testosterone, we also 
wanted to examine whether the reduced S-testosterone was associated with erectile 
dysfunction. Questionnaires (IIEF) were returned from 241 patients a median of 4.5 years 
after surgery. The median age was 67 years. 
 RT+ patients (n = 108) had significantly poorer scores for erectile function, orgasmic 
function, intercourse satisfaction and overall satisfaction with sex life compared with RT- 
patients (n = 133). In multiple, age-adjusted analysis, the odds ratio for moderate-to-severe 
erectile dysfunction in RT+ patients was 7.3 compared with RT- patients (CI = 3.3-16.0, p
<0.001). Moderate-to-severe erectile dysfunction was associated with low S-testosterone (CI 
(OR) = 1.5-32.5, p = 0.01).
Conclusions: RT for rectal cancer is associated with significant long-term effects on male 
sexual function, especially in terms of erectile dysfunction. 
PaperIV
The purpose of this study was to compare self-rated sexual function in female patients who 
had surgery for rectal cancer and either RT or no RT, at least 2 years after surgery. We 
aimed to use a questionnaire designed for use in female cancer patients, to assess side 
effects from pelvic radiotherapy in women. Questionnaires were returned from 172 patients, 
a median of 4.5 years after surgery. The median age was 65 years. 
Among the responding RT+ patients (n = 62) and RT- patients (n = 110), there were no 
differences in the frequency of being sexually active, in sexual interest or in worries about 
sex life. In sexually active women (n = 55), RT+ women reported more vaginal problems in 
terms of vaginal dryness (50% vs 24%), dyspareunia (35% vs 11%) and reduced vaginal 
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dimension (35% vs 6%) compared with RT- patients; however, they did not have significantly 
more worries about their sex life. 
Conclusions: The present study indicates that women treated for rectal cancer with pre- or 
postoperative (chemo-) RT and surgery have an increased risk of vaginal problems at long-
term follow-up, compared with women treated with surgery alone. However, to what extent 
these symptoms have an impact on sexual function is not clear.

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5.   DISCUSSION 
Methodologicalconsiderations
Among the strengths of this study is the use of a national cohort, because all patients alive 
who had been treated with RT for rectal cancer in the period 1993-2003 were identified. The 
access to treatment- and cancer-specific data from the Norwegian Rectal Cancer Registry, 
and data from the patients’ RT hospital- charts, along with patient-reported outcomes, made 
a comprehensive analysis possible.  
In clinical trials, analytical data (laboratory/imaging) are preferred endpoints because these 
can be validated across observers. Semiquantitative observer-based measures such as 
endoscopic findings, histological changes and physiological tests are also important in the 
understanding of the pathogenesis of radiation side effects. Nevertheless, these findings do 
not always correlate well with the patient’s symptoms (136, 137). Despite a low specificity in 
patient-reported outcomes and QoL, these are often the most relevant endpoints to the 
patient (Figure 4). This trade-off between patient relevance and specificity has been 
described by several authors (138, 139).  

 
Figure4.Illustrationofthetradeoffbetweenspecificityandpatientrelevanceofdifferentmeasures
ofsideeffects(withpermissionfromK.Jensen)(139)   
Patient-reported symptoms are often underreported or underestimated in clinical trials (140, 
141). Furthermore, less severe morbidity, such as occasional faecal incontinence, may be 
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undetected in retrospective studies of hospital charts, as these rarely result in admittance to 
hospital. Reporting of treatment-related morbidity is also highly dependent on the methods 
used. This was demonstrated by one study, which uncovered 22 times more adverse events 
when using a detailed patient-reported questionnaire compared with unstructured reporting 
(142). Ideally, validated scoring tools are preferable; however, most physician-scored toxicity 
scales have not been formally validated. We therefore aimed to use a structured and detailed 
questionnaire, which was based on relevant and widely accepted scoring systems, for 
assessing late morbidity in bowel and bladder. 
Prolonged observation is necessary because late morbidity after RT has shown a wide range 
of latency times, and may not become clinically manifest until several years after treatment. 
One of the strengths of this study is the follow-up time since treatment of between 2 and 13 
years. Only a few studies have evaluated late adverse effects more than 2 years after RT 
with 50 Gy in rectal cancer patients (40, 42, 76, 143, 144). Most of these studies were 
conducted before the introduction of modern surgery (TME and stapling technique) and had 
used a different RT regimen.  
In a cross-sectional study, only a “snap-shot” of the patients’ situation was obtained with no 
information about changes over time or the sequence in the time of the development of 
symptoms and the exposure (RT). It is therefore not possible to establish causal 
relationships from the current study. A prospective design would have provided more 
information about the time factor and the actual number of patients at risk, and such studies 
should be conducted in the future. 
 
Selectionbias
In this cross-sectional study, the patients and disease- and treatment-related data were 
sampled from a large, unselected, national patient registry, the Norwegian Colorectal Cancer 
Registry. However, because of the study design, the clinical picture in patients who have 
deceased or developed metastases is unknown, and the results should therefore be 
interpreted with caution. In attrition analyses, the responders and non-responders did not 
differ with regard to type of surgery, whether or not RT was used, T-stage or treating 
hospital, but responding patients were younger and had a shorter time since surgery. One 
explanation might be that patients treated several years ago consider themselves “healthy” 
and do not want to attend the study and thereby be “reminded” of the disease; in that case 
symptoms may be overreported. On the other hand, older non-responders might have more 
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morbidity, making them less capable or willing to participate. In that case, side effects might 
have been underreported.  
The study had a fairly low response rate among patients aged older than 70 years, and the 
results in the oldest age group are therefore prone to be affected by selection bias. Non-
responders tend to be less healthy in questionnaire-based surveys (145) and this may have 
lead to an underestimation of health problems in both groups of patients. However, when the 
analyses for bowel function, urinary function and QoL were repeated, excluding patients 
aged over 70, the estimated differences between RT+ and RT- patients remained 
unchanged.   
 
Confoundingfactorsandsamplesize
As a result of the study design, there were differences in tumour characteristics between the 
two treatment groups. Patients were treated with RT preoperatively because of T4 tumour, 
tethered tumour, potentially threatened resection margins or postoperatively because of 
involved resection margins. Furthermore, RT+ patients had tumours closer to the anal verge 
and were more often treated with chemotherapy. When designing the study we chose not to 
match for potentially confounding factors, because variables used for matching cannot later 
be investigated as possible risk factors. Instead, confounding factors (identified from both 
searching the literature and biological considerations) were adjusted for in multiple 
regression analyses. Nevertheless, there are some limitations to this strategy; the possibility 
for adjusting for confounders is limited when the event is rare; as a rule of thumb the number 
of covariates in a regression model should not generally exceed about 10-15% of the number 
of events. Furthermore, in analyses with using low numbers of patients, there is a risk of not 
detecting existing differences (type II statistical error). These problems are particularly 
relevant in papers III and IV as the numbers of patients who had been sexually active were 
limited in this elderly population.  
An important possible confounding factor is the fact that about half the irradiated patients had 
received concomitant chemotherapy. 5-FU-based chemotherapy is known to increase the 
acute toxicity in rectal cancer treatment (50). Few studies have assessed this issue in long-
term follow-up. A Polish study compared short-course RT with CRT and found no difference 
in QoL or in late toxicity after 4 years of follow-up (49).  
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Informationbias
Information bias may occur if the reliability of the information or data differs systematically 
between patients and controls. In this study, the interviewer was not blinded to whether 
patients had been treated with RT, which may have led to a worse scoring of exposed 
patients. However, the interview was based on a structured questionnaire with given 
response alternatives for most of the questions, e.g. the patients were asked if their daily 
defecation frequency was 0-1, 2-4, 5-7, >8 or uncontrolled diarrhoea. Furthermore, none of 
the three interviewers had treated the patients in the study, thereby avoiding a situation 
where patients could theoretically give “pleasing” answers. For the self-administered 
questionnaires, we used questionnaires that had been extensively validated and translated 
according to international standards.  
To reduce inaccuracy in recalled information, we used the time frame of 1 month for the 
questions about bladder and bowel function and did not ask the patients to compare 
symptoms or function with how it was before the cancer treatment.    
  
Discussionofthemainfindings
Bowel,anorectal,andbladderfunction
In paper I we found that RT for rectal cancer was associated with considerable late side 
effects on bowel and anorectal function, especially in terms of increased bowel frequency, 
urgency and faecal incontinence. 
In patients without a stoma, 49% of the irradiated versus 15% of the non-irradiated patients 
were incontinent for liquid stools, 52% versus 13%, respectively, needed pads and 44% vs 
16%, respectively, lacked the ability to defer defecation. These findings are quite similar to 
those of other studies. In the Stockholm Radiotherapy Trials (25 Gy), the frequency of faecal 
incontinence was 57% in irradiated (n = 21) and 25% in non-irradiated patients (n = 43) 14 
years after treatment (112). The Dutch TME study found a frequency of faecal incontinence 
of 62% in the preoperative RT- arm and 38% in the surgery-alone arm after a follow-up of 5 
years. There are only a few reports on long-term morbidity in bowel and anal function after 
RT with 50 Gy. In a retrospective, single-centre study comparing patients treated with 
postoperative CRT with patients treated with surgery alone, Kollmorgen et al. reported 
increased frequency of daily bowel movements (7 vs 2, respectively), more faecal 
incontinence (39% vs 17%, respectively) and a higher proportion of patients unable to defer 
defecation 15 minutes (78% vs 19%, respectively) (76). Another Danish study with a follow-
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up of 11-20 years found that patients who had undergone postoperative RT had significantly 
increased stool frequency and more often liquid stool, and a higher proportion had faecal 
incontinence and used pads (143, 144). 
As only high-risk patients received RT, the two treatment groups in our study were different 
in many respects. RT+ patients had a higher prevalence of tumours situated in the distal 
rectum, and a higher proportion had stage pT3-4 tumours. We found a significant effect of 
tumor height on faecal incontinence in analysis with multiple explanatory variables. Tumour 
height and level of anastomoses as risk factors for faecal incontinence have been studied by 
others. In a previous study from the Norwegian Rectal Cancer Registry, patients with very 
low anastomoses (3 cm from anal verge) had more incontinence than patients with higher 
anastomoses, but there was no linear relationship between the two (114). In the TME study 
(146), Lange et al. observed that, in the RT group, but not in the surgery-alone group, 
patients with tumours closer to the anal verge had an increased risk of faecal incontinence 
compared with patients with higher situated tumours. In this study tumour height determined 
the lower border of the radiation field, and the data also showed an increased risk of faecal 
incontinence (relative risk 7.45, p = 0.059) in patients where the perineum was included in 
the radiation field. In the Swedish Rectal Cancer Trial, anastomotic height had no effect on 
bowel function in the long-term follow-up (75). 
T-category, on the other hand, was not a significant covariate for either faecal or urinary 
incontinence in analyses with multiple explanatory variables. As a result of the low number of 
T4 tumours in the control group (n = 7) we also analysed T-category as a dichotomized 
variable (T1 and T2 tumours or T3 and T4 tumours); however, this did not change the 
outcome. There was no effect of TNM stage on the risk for faecal incontinence in either the 
TME study or the Swedish Rectal Cancer Trial. However, in both the Dutch and the Swedish 
trials, only primarily resectable cases were included, whereas our study also included 
patients with tumors that were not primarily resectable (T4 and tethered tumours). In another 
study, 43 disease-free patients, previously treated with extended TME and RT for locally 
advanced or locally recurrent tumours, reported more defecation problems and pain, and 
lower scores for several QoL scales compared with patients with primarily resectable 
tumours (147).  
It is well known that surgery for rectal cancer may have significant morbidity in relation to 
bowel and bladder function (148, 149). However, with a median follow-up time of almost 5 
years since surgery, the side effects of surgery were expected to have stabilized. This is 
supported by the findings in the Dutch TME study: at follow-up during the first 2 years after 
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treatment, the percentage with faecal incontinence decreased significantly in patients treated 
with RT as well as in patients treated with surgery alone and, except for a slower recovery of 
bowel function, there were few differences in QoL between patients treated with and those 
not treated with RT (98). However, comparing the results at 2 and 5 years of follow-up, the 
percentage of patients with incontinence had increased significantly in the RT group (from 
52% to 62%), but not in the surgery-alone group (36% and 39%, respectively) (77, 146). 
Furthermore, the degree of incontinence was worse in the RT group compared with the 
surgery-alone group. 
Qualityoflife
The QoL analysis did not demonstrate major differences between patients who were RT+ 
and RT-. Similarly, no major differences were detected when the RT group was compared 
wiht age- and gender-adjusted values from the general population. Nevertheless, irradiated 
patients had impaired social function compared with non-irradiated patients, and patients 
with frequent faecal or urinary incontinence had impaired scores for several aspects of QoL. 
Impaired social function in RT+ patients is quite in accordance with data from the Swedish 
Rectal Cancer Trial. Similar to us, they found only small differences in scores on the QLQ-
C30 between RT+ and RT- patients, and between the study population and norm data from 
the Swedish population (82). The authors also demonstrated that patients with faecal 
incontinence had significantly impaired scores for all four subscales of the “Fecal 
incontinence quality of life”- scale (112). Also, in the Dutch TME study, the authors found no 
difference in QoL between patients treated or not treated with RT (98). However, the study 
used another questionnaire, the Rotterdam Symptom Check List, and social function was not 
assessed.  
In our study, a higher percentage of RT+ compared with RT- patients had a permanent 
stoma. Some previous studies have demonstrated that patients with colostomy have 
impaired QoL  (150, 151); others have found no difference or even better QoL scores in 
stoma compared with non-stoma patients (114, 152, 153). In our study, a stoma was not 
associated with impaired QoL. On the contrary, stoma patients reported fewer limitations in 
their social lives than patients without a stoma. One explanation may be that patients with a 
well-functioning stoma are less “toilet-dependent” than patients with various degrees of 
faecal incontinence. In Norway, stoma patients are followed closely and specially trained 
“stoma- nurses” are available to many patients for advice and assistance. In addition the 
patients in our study have had some time to adapt to living with a colostomy.  
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Several other studies have shown no or minor differences in QoL of a cancer population and 
a healthy “normal” population. This phenomenon, referred to as “response shift”, is often 
attributed to the fact that patients adapt to their situation over time, and that their perceptions 
of QoL may change (154), e.g. some patients might consider living with a stoma to be a 
small price for being cured from a life-threatening malignant disease, leading to a 
“recalibration” of their own internal standards and values. 
 
Malesexhormones
The results in paper II indicate that pelvic RT for rectal cancer increases the risk of 
permanent testicular dysfunction, in terms of elevated levels of gonadotrophins along with a 
less pronounced decrease in S-testosterone. To our knowledge this is the first report on male 
sex hormones in long-term follow-up after RT for rectal cancer.  
Recently, two Canadian publications have assessed these questions and reported similar 
results. One prospective study in 43 men reported an almost fivefold peak in FSH levels and 
doubled LH levels, in a follow-up period of 6 years after CRT for rectal cancer (155). The 
mean testosterone level decreased throughout follow-up from 15.4 nmol/L pre-treatment, to 
11.9 nmol/L at 13-24 months and 8 nmol/L more than 48 months after CRT. The patients had 
been treated with a three- or four-field technique, and with doses of 1.8 Gy to a total dose of 
54 Gy, and the median dose to the testicles was measured (in five patents) to 4 Gy (range 
1.5-8.9). In another study, 51 patients treated with conventional external beam CRT (45-50.4 
Gy) were compared with 38 patients treated with brachytherapy at a high dose-rate (26 Gy 
over four daily treatments of 6.5 Gy) (156). Two years after treatment, gonadotrophins were 
elevated in all patients, but more pronounced in the CRT group. The mean cumulative dose 
to the testicles in the two groups was 1.24 Gy and 0.27 Gy, respectively.  
Chemotherapy, most commonly 5-FU, was given with RT in 30-100% of the patients in the 
above-mentioned studies. FLv was given with RT to 53% of the patients in our study and we 
found no association between testosterone level and chemotherapy. One animal study 
observed decreased testosterone values and degeneration of the seminiferous epithelium in 
rats treated with 5-FU, but no histological changes were observed in the Leydig cells (157). 
The long-term toxicity of 5-FU on the Leydig cells in humans is unclear, and there is, at the 
present time no knowledge about the impact of more potent chemotherapy on gonadal 
function. 
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Malesexualfunction
The mean score for erectile function was poor in both treatment groups (RT+ and RT-). This  
was not unexpected because rectal cancer surgery may cause damage to pelvic autonomic 
nerves resulting in erectile dysfunction (ED) and/or retrograde ejaculation (105, 158-160). 
However, males treated with RT and surgery had significantly poorer scores for erectile 
function, orgasmic function, intercourse satisfaction and overall satisfaction with sex life, but 
not for sexual desire, compared with men treated with surgery alone. The negative 
association between RT and erectile function remained significant when adjusting for 
possible confounding covariates such as age, type of surgery (AR or APR), T-stage and 
tumour height. ED is a well-known sequela after pelvic RT for prostate cancer. However, it is 
still debated whether ED after pelvic RT for prostate cancer  is due to sequelae to the pelvic 
arteries, the veno-occlusive mechanisms in the corpora cavernosa or to the neurovascular 
bundles (161, 162). 
To our knowledge, this is the first report on male sexual function after RT with 50 Gy 
assessed with a comprehensive questionnaire using established psychometric properties. 
The IIEF has been widely used in clinical trials and translated into many languages, among 
them Norwegian. However, in our experience the questionnaire has some limitations. 
Ejaculatory disorders, which have been reported after rectal cancer treatment (98), are not 
assessed. Furthermore, relationship-related issues are not covered in the questionnaire, 
making it difficult to differentiate between men who are sexually continent because of ED and 
those abstaining from sexual intercourse for partner-related reasons (e.g. partners with poor 
health, being a widower, etc.). The Male Sexual Health Questionnaire (MSHQ) was 
developed in 2004 to address these limitations (163), but the questionnaire was not available 
in Norwegian at the time of the study.  
ED is a disorder with a high prevalence and the incidence increases steadily with age (164, 
165). Furthermore, the ageing process in males is accompanied by a decline in S-
testosterone (166). The interrelationship of RT for rectal cancer, testosterone and erectile 
function has to our knowledge never previously been assessed. We found that moderate-to-
severe ED was statistically significantly associated with low S- testosterone in multivariable 
analysis with RT, age and S-testosterone as explanatory variables (OR = 6.3, CI = 1.5-32.5). 
Nevertheless, because of the broad confidence interval this finding should be interpreted with 
caution. Androgens act at several sites in the sexual response system: within the central 
nervous system and peripheral nerves, and finally a direct effect of androgens on the corpora 
cavernosa (87, 167, 168), although contradictory results exist (169). Recent studies have 
shown that ED is associated with both physical and mental health, indicating that sexual 
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function is complex, and ED is not easily attributed to a single pathogenic cause (170). 
However, information before treatment about an increased risk of hypogonadism and sexual 
dysfunction is warranted.  
 
Femalesexualfunction
RT+ women reported significantly more vaginal problems in terms of vaginal dryness, 
dyspareunia and reduced vaginal dimension, but not impaired sexual interest or more 
worries about sex life compared with women treated with surgery alone.  
It is known that radiation to the internal female genitals may lead to vaginal atrophy, fibrosis 
and adhesions of the vaginal wall (102, 171, 172). Narrowing and shortening of the vagina 
may evolve, often together with pelvic fibrosis and loss of vaginal elasticity. Furthermore, 
menopause is associated with vaginal atrophy and dyspareunia, and radiation-induced 
ovarian failure is inevitable in premenopausal women, because the ovaries are located in the 
radiation field. 
Only one large randomized trial, the Dutch TME study, has assessed sexual function in 
women after RT for rectal cancer (98). They found that RT was associated with sexual 
dysfunction, similar to our study. However, in contrast they found no increase in vaginal 
dryness or dyspareunia, but a decrease in sexual interest, pleasure and satisfaction. The 
Dutch study was conducted from 3 months- to 24 months after treatment, whereas our 
results were based on questionnaires completed 31-125 months after treatment. The time 
since RT may have influenced the results, as radiation late effects could have long latency 
times. Another difference between the two studies was that, although CRT was not used in 
the Dutch study, chemotherapy with 5-FU was given together with RT to 63% of the women 
in our study. Chemotherapy with 5-FU may in theory enhance the late effects of RT on the 
vaginal mucosa; however, this has to our knowledge not been documented. An independent 
effect of chemotherapy on vaginal changes could not be shown in the current study. 
The low numbers of sexually active women limits the possibilities of adjusting for potentially 
confounding factors in this study. Furthermore, the SVQ measures vaginal symptoms in 
sexually active women only, and gives no information about symptoms in women who had 
not had recent sexual intercourse. It is possible that the women, who had not had intercourse 
have vaginal problems that have not been reported. 
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Preventionofsideeffects
The most important method of decreasing the irradiation dose to the small bowel during 
pelvic RT is the use of multiple radiation fields. Treatment with three to four fields significantly 
decreases the volume of small bowel compared with a two-field technique, and is now 
considered standard treatment in most countries. Other measures that have been taken to 
reduce the dose to the small bowel are: patient treatment in a prone position, the use of a 
belly board, and patient instructions to drink water to increase the bladder filling (173).  
 
For patients with tumours situated in the upper part of the rectum, who are treated with 
sphincter-preserving surgery, the caudal field edge should be placed so that the sphincter is 
spared.  Al-Abany et al.  found a dose-volume effect between the dose to the anal sphincter 
region and the risk of faecal leakage in 65 patients with prostate cancer (174). However, the 
functional tolerance dose of the anal sphincter is not known, and faecal continence is also 
dependent on the capability of the rectum to act as a reservoir. A decrease in rectal 
compliance is often seen after RT for rectal cancer because the rectum is part of the target 
volume for radiotherapy (175), but is also seen after complications of surgery (176). 
To reduce the testicular dose, treatment using the centre of the radiation field placed far 
caudal in the target (half-beam technique) was recently compared with standard treatment 
technique in a study on 22 patients from our institution (177). An average 48% reduction in 
testicular dose was achieved, while the dose to the target volume was maintained. A half- 
beam technique is simple to use, and could be an alternative or supplement to other 
methods for reducing testicular dose; however, the method needs further validation. Others 
have suggested the use of a double-hole belly board or a lead shield (178-180). These 
techniques have not been integrated into clinical practice in the treatment of rectal cancer, 
and so effect in preventing testicular dysfunction is not known. 
The dose-volume relationship in ED is not established. Exclusion of the penile bulb, 
neurovascular bundles, penile crura or corpora cavernosa of the radiation field has been 
suggested, but the results are inconsistent (181). 
Prevention of radiation-induced vaginal stenosis is facilitated with the use of vaginal dilators 
and such devices should therefore be recommended (182). The evidence for use of topical 
oestrogens to prevent vaginal bleeding and dyspareunia is less clear and needs to be 
confirmed in larger studies.  
Currently, with the use of intensity-modulated radiotherapy (IMRT) it is possible to create a 
more conformal treatment plan that has a similar target coverage and a large reduction in 
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dose to the organs at risk (OAR) compared with conventional techniques (183, 184). 
However, IMRT will inevitably increase the irradiated volume in the low-dose range because 
of the use of multiple fields and the impact on late morbidity, in particular the risk of 
secondary cancers, needs to be further studied. 
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6.  CONCLUSION 
 
Improvements in treatment of rectal cancer have resulted in reduced frequency of local 
recurrence and an increasing number of long-term survivors. In Norway, a larger proportion 
of patients have been treated with preoperative RT over the last few years. The papers of 
this thesis have focused on late morbidity and quality of life in long-term survivors after RT 
for rectal cancer.  
We found that RT+ is associated with considerable late side effects on bowel and anorectal 
function, especially in terms of increased bowel frequency and increased risk of faecal 
incontinence. In particular, the risk of incontinence for loose stools, the need for sanitary 
pads and faecal urgency were higher in patients treated with compared with those not 
treated with RT. Urinary incontinence also occurred more frequently in RT+ compared with 
RT- patients.  
More male RT+ than RT- patients had increased levels of serum gonadotrophins and 
subnormal levels of serum testosterone, indicating permanent testicular dysfunction. Further 
studies are needed to evaluate the impact of Leydig cell dysfunction on morbidity and quality 
of life in these patients.  
The risk of male sexual dysfunction, in particular moderate-to-severe ED, was high in both 
treatment groups; however, it was significantly higher in RT+ compared with RT- patients. 
Female RT+ patients more often experienced vaginal problems than women treated with 
surgery alone. No impairment in sexual function was disclosed in women treated with RT. 
More studies are needed in order to clarify the effect of RT on female sexual function. 
Global QoL was not impaired in RT+ patients compared with either RT- patients or values 
from the general Norwegian population. However, RT+ patients had lower scores for social 
function, compared with either patients treated for rectal cancer with surgery alone or with 
the general population. Patients with faecal incontinence had impaired scores for several 
aspects of QoL compared with continent patients. 
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7.   FUTURE PERSPECTIVES 

Cancer treatment, including surgery, RT and chemotherapy, are associated with a spectrum 
of normal tissue effects and there is no therapeutic gain unless advances in tumour control 
are balanced against the treatment-related morbidity. As improvements and changes in the 
treatment of cancer result in large numbers of long-term survivors, knowledge about patients’ 
QoL becomes increasingly important. The study of normal tissue side effects from RT should 
be an integrated part of the quality assurance of cancer treatment. Information must be 
prospectively collected and include patient-reported as well as physician-assessed morbidity. 
As RT is often part of a multimodality treatment, side effects from surgery and chemotherapy 
need to be assessed as well. Uniformity in reporting side effects increases the value of the 
data, and standardized reporting should be preferred. Further studies are needed to 
establish the dose-volume relationship for late morbidity and, furthermore, to develop 
strategies for prevention and treatment of these.  
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Errata
Paper I: Study design: “we identified all male patients” should be “we identified all patients (male and 
female)”….  
Paper II: Identified male patients should be 620 and eligible male patients 546. 
 
 
 
Erratum list for 
“Late side effects and quality of life after radiotherapy for rectal cancer” 
 
-Page 5, line 6: the correct meaning of the abbreviation CRM is “circumferential resection margin”.  
-Page 11, line 23: “...the Cancer Registry of Norway, to which all cancers in Norway are reported.” (the 
word institution is omitted)
-Page 32, line 17-18: ” The aims of the study were to examine whether RT for rectal cancer was 
associated with reduced S-testosterone and whether male hormonal status was associated with RT 
treatment-related factors.” (the word both is omitted and whether  is added) 
- Page 37, line 24: the correct numbers are papers III and IV  
-Page 40, line 16: the correct name is The Swedish Rectal Cancer Trial 
-Page 43, line 17: “...., but a decrease in sexual interest, pleasure and satisfaction.” (the word 
dyspareunia is omitted and satisfaction is added) 
 
Kjersti Bruheim 
January 26, 2010 
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Abstract 
Background: Knowledge about female sexual problems after pre- or postoperative 
radiotherapy (RT) and radical resection of rectal cancer is limited. The aim of this 
study was to compare self-rated sexual functioning in women treated with or without 
RT (RT+ vs RT-), at least two years after surgery for rectal cancer. 
Methods and materials: All surviving female patients diagnosed from 1993 to 2003 
were identified from a national database, the Norwegian Rectal Cancer Registry. 
Eligible patients were without recurrence or metastases at the time of the study. The 
Sexual function and Vaginal Changes Questionnaire (SVQ) was used to measure 
sexual functioning. 
Results: Questionnaires were returned from 172 out of 332 invited and eligible 
women (52%). The mean age was 65 years (range 42-79) and the time since 
surgery for rectal cancer was 4.5 years (range 2.6- 12.4). Sexual interest was not 
significantly impaired in RT+ (n=62) compared to RT- (n=110) women. RT+ women 
reported more vaginal problems in terms of vaginal dryness (50% vs 24%), 
dyspareunia (35% vs 11%) and reduced vaginal dimension (35% vs 6%) compared 
with RT- patients; however, they did not have significantly more worries about their 
sex life. 
Conclusion: Several years after curative surgery for rectal cancer, vaginal problems 
are more often reported by women who had additional RT than by patients treated 
with surgery alone. Information about the increased risk of side effects affecting 
sexual function should be provided to these patients.  
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Introduction 
Rectal excision is associated with a risk of sexual dysfunction due to pelvic 
autonomic nerve damage, tissue trauma, and scarring [1-4]. Pre- or postoperative 
(chemo-)radiotherapy (RT) is part of the multimodality treatment of rectal cancer.  
Preoperative RT reduces the frequency of local recurrence after total mesorectal 
excision (TME) compared to surgery alone [5].  
Pelvic radiotherapy may cause adverse effects in normal tissue [6]. Clinical studies 
have shown that patients treated with radiotherapy for cervical cancer have an 
increased risk of vaginal problems and sexual dysfunction [7-9]. Furthermore, it has 
recently been shown that patient-reported symptoms are often underestimated by 
physicians [10].   
Few studies have assessed the effect of RT on sexual function in female rectal 
cancer patients. In the Dutch TME study, it was observed that preoperative short-
term RT (5 Gy x 5) had a negative impact on sexual activity and sexual function 
[11,12]. An American study suggested that female rectal cancer patients treated with 
radiotherapy had a 4-fold increase in dyspareunia compared to surgery-only patients 
[13]. With exception of intercourse frequency, binary (yes/no) outcomes were 
recorded.  The response rate for questions about sexual function was 40-50 percent. 
Both these studies used non-validated questionnaires for sexual function. 
The purpose of the present cross-sectional study was to compare self-rated sexual 
function in female patients, who had undergone surgery for rectal cancer, and had 
received (RT+) or not received (RT-) adjuvant radiotherapy. We used a validated 
questionnaire which assessed sexual side effects, that was designed for female 
5 
 
cancer patients that had been treated with pelvic radiotherapy. Our hypothesis was 
that RT+ patients, compared to RT- patients, had significantly impaired sexual 
function, and more vaginal problems in terms of dryness, dyspareunia, and reduced 
vaginal dimension.
6 
 
Material and methods  
Patients were identified from a national database, the Norwegian Rectal Cancer 
Registry (NRCR), which is part of the Cancer Registry of Norway, and includes all 
patients with rectal cancer in Norway diagnosed since November 1993. The NRCR 
contains data on tumor characteristics, the primary treatment, and consecutive 
information about recurrences and metastases from all hospitals in Norway treating 
rectal cancer, as well as dates of death.  
Study design 
For this cross-sectional study, we identified all surviving female patients, who had 
been diagnosed with primary rectal cancer from November 1993 to December 2003 
in the NRCR, and who had been treated with pre- or postoperative (chemo-) RT with 
curative intention (n= 170) and were without local recurrence or distant metastases. 
To serve as controls for the irradiated (RT+) patients, female patients treated with 
surgery alone (RT-) in the same time period were sampled from the NRCR (n=370). 
The controls were drawn randomly and were not matched for age, treatment- or 
disease-related factors, in order to allow analyses of the effects of these variables. 
Potential confounding factors were adjusted for in multivariable statistical analyses 
when possible. The identified patients were eligible for the study if they had been 
treated with a major resection (low anterior resection, abdominoperineal resection, or 
Hartmann’s procedure), had at least two years of follow-up since surgery and were 
without recurrence or metastases.  
All patients were invited by mail to participate in the study. Two reminders were sent 
to non-responders after approximately two and four weeks. Patients, who returned 
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an informed consent, were thereafter asked to complete the Sexual function and 
Vaginal Changes Questionnaire (SVQ) and to participate in a telephone interview.  
Patients were excluded from the analyses if the telephone interview disclosed that 
they had developed local recurrence or distant metastases at the time of the study, 
or if they had received pelvic RT for other malignancies (e.g. uterus or cervix 
cancer). 
Our study was part of a national study assessing late effects from RT for rectal 
cancer without an upper age limit. However, in the analysis of sexual function, only 
women younger than 80 years were included, because we anticipated that very few 
women beyond this age are sexually active.  
Sexual function 
The SVQ is a 17-item questionnaire designed and previously validated to assess 
sexual function and vaginal changes in patients with gynaecological cancer [14]. The 
Danish version of the SVQ was obtained from the author of the original validation 
study and a forward-backward translation was performed. The interpretation of the 
final version was pilot tested in 10 female patients with rectal cancer undergoing 
treatment at our department. The questions were considered to be relevant also for 
women treated for rectal cancer, although the SVQ has not been validated for this 
patient group. 
The questionnaire consists of two parts; the first part is answered by all respondents 
and concerns intimacy, sexual interest, sexual satisfaction and worries about sex-
life. The second part is completed only by women who have been sexually active 
during the last month. This part includes a symptom scale on vaginal changes (VC) 
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comprised of the sum of two questions about lack of lubrication and two on 
dyspareunia (Table 1). Furthermore, there is one question about reduced vaginal 
dimension, and two about bleeding during intercourse. Finally, there is a sum score 
of sexual functioning (SF) comprised of the ability to complete intercourse, orgasm, 
and relaxation after sexual activity. The responses are scored into four categories 
(“not at all”, “a little”, “quite a bit”, and “very much”) that are transformed into a 1-4 
scale. In the original questionnaire questions about ability to complete intercourse 
and orgasm were scored into the categories “never”, “occasionally”,” often”, “always”, 
but these questions were inadvertently scored into the categories “not at all”, “a 
little”, “quite a bit”, and “very much”. For the multivariable analyses the responses 
were dichotomized into “quite a bit/very much” or “not at all/ a little”. Two questions 
(about satisfaction/dissatisfaction with sex life and appearance) are scored on a 
Likert scale ranging 1-7. A higher score on a symptom scale or question represents 
more symptoms, and a higher score on a function scale represents better 
functioning. The time frame of the SVQ is the last month.  
 
Telephone interview data 
Information about current medication, working status, concomitant disease (diabetes 
and hypertension), smoking, and presence of stoma was obtained in a structured 
telephone interview performed by a research nurse or a physician (first author). 
 
Radiotherapy  
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The standard preoperative and postoperative radiotherapy consisted of 25 daily 
fractions of 2 Gy given in five weeks. The pelvic RT was delivered with a three- or 
four-field technique or two field technique, and 6-18-MV photon beams. In most of 
the period, the RT treatment planning was based on two-dimensional simulation, 
usually with 3 standard fields; the cranial field border at the L5-S1 interspace, the 
lower border close below the anal verge or 3 cm above for more proximal tumours, 
and the lateral border close to the linea terminalis. An increasing proportion of the 
patients irradiated after the year 2000 had CT-based 3D treatment planning. In most 
cases, chemotherapy consisted of bolus 5-fluorouracil (5-FU) and leucovorin 
according to the Nordic regimen [15,16]. Information on RT dose, number of fields, 
treatment time, patient positioning, and concomitant chemotherapy was obtained 
from hospital charts 
Statistics 
Data were analyzed with SPSS version 16.0 (SPSS Inc, Chicago, IL). Mann Whitney 
U-test was used to compare groups with continuous variables. Pearson chi-square 
test was used for categorical data.  
If at least half of the items from the scale had been answered, the missing item was 
assumed to have values equal to the average of those items which was present. 
Based on the recommendations from the QLQ C-30, the total scale score was 
considered to be missing if less than half of the items from the scale had been 
answered [17].  
Logistic regression analyses were performed to adjust for potentially confounding 
factors. For these analyses the responses to the question about sexual interest and 
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the second part of the questionnaire (answered by sexually active women only) were 
dichotomized into “quite a bit / very much” or “not at all / a little”. The dichotomized 
scores were used as dependent variables, and RT, age, and stoma as independent 
variables.  All tests were two-tailed, and a p-value <0.05 was considered as 
statistically significant. 
Ethics 
The study was approved by the Regional Committee for Medical Research Ethics, of 
South Eastern Norway. 
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Results 
Patients and treatment 
A total of 540 females with primary rectal cancer were identified from the NRCR. Of 
these, 208 were non-eligible (37 local surgery, 11 deceased or not able to give 
informed consent, 5 recurrence or pelvic RT for another malignancy and 155 age 
≥80 years); thus 332 women were eligible. Of these, 172 women (52%) returned 
completed questionnaires (62/118 RT+ and 110/214 RT-); however, not all questions 
was answered by all responders. 
Responders and non-responders did not differ with respect to type of surgery, T-
category, or time since surgery; however, responding patients were younger (median 
65 vs. 73 years, p<0.001).  
Among the responders, 45 patients in the RT+ group (74%) and 73 (69%) in the RT- 
group had a partner (p=0.5). Among the 118 women with a partner, the median age 
was 62 years among those who were sexually active (n=56), and 67 years among 
those who were not (n=62). RT+ patients had a shorter median interval since surgery 
than RT- patients. As a consequence of the selection-criteria for RT, a higher 
proportion of RT+ patients had pT4 tumours, tumours closer to the anal verge, had 
undergone abdominoperineal resection and had a stoma compared to RT- patients 
(Table 2). In 19 of the RT+ patients (31%) and 15 of the RT- (14%), the resection 
included the vagina or internal genitals. TME was performed in 96% of all patients. 
RT was given preoperatively in 33 patients (53%) and postoperatively in 29 patients 
(47%). The mean dose to the gross tumor volume was 50 Gy (range 34-60). Most 
patients (97%) were treated with ≥3 fields, 44% in supine and 56% in prone position. 
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Concomitant chemotherapy was given to 39 of the RT+ patients (63%); all had 5 FU 
based chemotherapy, and in 3 patients oxaliplatin was also given. Chemotherapy 
was given to 18 of the patients (55%) who received preoperative radiotherapy, and 
to 21 of the patients (72%) who received postoperative radiotherapy. Only two RT- 
patients had received chemotherapy. 
The self-reported prevalence of diabetes (4%), hypertension (29%), current smokers 
(22%), or women currently employed (32%), did not differ significantly between the 
RT+ and RT- groups. Eight RT+ women (13%) and 11 RT- women (10%) reported to 
use oestrogen replacement therapy or topical oestrogens (p=0.6).  
 
Female Sexual Function 
There was no significant difference in the score for intimacy, sexual interest, or 
worries about sex life between RT+ and RT- patients (Table 3). A total of 56 women 
had been sexually active the last month, 20 in the RT+ group and 36 in the RT- 
group, (representing 44% of RT+ and 47% of RT- women with a partner, p=0.9). 
When comparing patients with or without a present stoma, there were no statistically 
significant differences in the proportion of patients who reported being sexually 
active (42% vs. 49%, respectively, p=0.4) or in the score for 
satisfaction/dissatisfaction with appearance (mean 4.6 vs. 4.9, respectively, p=0.3). 
Increasing age was significantly associated with less sexual interest and less sexual 
activity (data not shown).  
In sexually active women, the mean score for VC (lack of lubrication during 
intercourse and dyspareunia), reduced vaginal dimension and vaginal bleeding 
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during intercourse was significantly higher in the RT+ group compared to the RT- 
group (Table 3). However, there was no significant difference in the score for sexual 
functioning (SF) between the two treatment groups. In the RT+ group 50% (10/20) 
reported vaginal dryness, compared with 24% (8/34) in the RT- group (p=0.046) 
(Table 4). For reduced vaginal dimension and dyspareunia the relevant figures were 
35% (7/20) vs. 6% (2/34) (p<0.01), and 35% (7/20) vs. 11% (4/36), respectively 
(p=0.03).  
In logistic regression analyses with vaginal or orgasmic problems as the dependent 
variable there was no significant effect of age, genital resection, chemotherapy or 
stoma in sexually active women (data not shown). However, the odds for lack of 
lubrication, dyspareunia, and vaginal constriction was increased in RT+ women 
compared to RT- women, and the effect  remained significant when adjusted for age 
and stoma (Table 4).  
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Discussion 
The present study indicates that women treated for rectal cancer with pre- or 
postoperative (chemo-)RT and surgery have significantly more vaginal problems at 
long time follow-up than women treated with surgery alone. On the other hand, 
sexual interest was not significantly impaired in RT+ compared to RT- women and 
RT+ women did not have significantly more worries about their sex life than RT- 
women.  To our knowledge this is the first study that assesses female sexual 
function in patients with rectal cancer in long term follow-up after RT with 50 Gy with 
a comprehensive questionnaire. 
There may be several reasons why women experience sexual problems after pelvic 
RT. Radiotherapy for rectal cancer includes a major part of the internal genitals 
which may lead to atrophy, fibrosis, adhesions, and shortening of the vagina [6]. 
Furthermore, the radiation field involves the ovaries. Radiation to the ovaries may 
cause permanent menopause after a total exposure of 4-7 Gy in women from about 
40 years and older [18]. The majority of the women diagnosed with rectal cancer 
have already reached the age of menopause; however, in premenopausal women 
radiation-induced ovarian failure may contribute to vaginal dryness and dyspareunia 
[19].  
 
Sexual function has been investigated in women treated with radiotherapy for 
cervical cancer [20]. A prospective study by Jensen et al observed persistent sexual 
dysfunction and adverse vaginal changes two years after radiotherapy for cervical 
cancer [8]. Also, Frumovitz et al found that women treated with radiotherapy had 
more sexual dysfunction and vaginal problems five years after treatment for cervical 
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cancer, than did those treated with radical hysterectomy and lymph node dissection 
[9]. On the other hand, Bergmark et al concluded that radiotherapy, compared to 
surgery alone had little, if any effect on the prevalence of vaginal shortness, 
inelasticity, or lubrication in a population of early stage cervical cancer treated with 
surgery and intracavitary radiotherapy and/or external radiotherapy [21].  
Radiotherapy for gynaecological and rectal cancer has similarities, and research 
results from patients with cervical cancer patients may to some extent be 
extrapolated to patients with rectal cancer. However, women with cervical cancer are 
likely to experience more symptoms as they are younger, and a larger proportion is 
premenopausal compared to women with rectal cancer. Furthermore, it may be more 
difficult to separate the sexual late effects on genital organs from surgery and those 
from RT in patients with gynaecological cancer.  
 
Several studies on rectal cancer patients show that sexual function deteriorates after 
surgery [1,3]. However, the effect of pelvic radiotherapy on female sexual function 
has been only briefly assessed in subgroup-analyses [3,22-24]. To our knowledge 
only one large, randomized trial has assessed sexual function in women after RT for 
rectal cancer [12]. The authors found that preoperative RT (5 Gy x 5) was associated 
with an increase in sexual dysfunction, similar to the results in the present study. The 
authors found no increase in vaginal dryness or dyspareunia following RT, but a 
decrease in sexual interest, pleasure and satisfaction [12]. The data were collected 
prospectively 3 to 24 months after radiotherapy, while the present results are based 
on a questionnaire completed 31-125 months after initial treatment.  The time since 
radiotherapy may influence the results, as late radiation effects are known to be 
cumulative with time and may have long latency times.  
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In the current study, the selection criteria for RT implies differences in tumour and 
treatment characteristics between RT+ and RT- patients. More RT+ patients had 
locally advanced tumours and tumours closer to the anal verge, and a higher 
proportion had abdominoperineal resection with a stoma, resection including the 
internal genitals or had adjuvant chemotherapy. We aimed to adjust for these factors 
in multiple regression analysis; however, the low number of sexually active women 
reduced the possibility to adjust for the desired number of potential confounders. 
Only about one third of the women had been sexually active the last four weeks, 
which is not unexpected in this elderly population. Others have found that patients 
who underwent APR were less sexually active, and that having a stoma was 
associated with sexual dysfunction [11,13].  
Like in many other studies of this intimate subject, the study had a fairly low 
response rate [1,9,25] which may lead to selection bias. The responding women 
were younger than the non-responding, which most probably have resulted in a 
selection of more sexually active women. Another limitation to the present study is 
that the SVQ assesses sexual function mainly by investigating vaginal symptoms 
and in sexually active women only. Therefore, sexual dysfunction in women without 
a partner is not evaluated. This may lead to underreporting, as women who are not 
sexually active may also have vaginal symptoms. Finally, the SVQ was designed 
and validated for women with gynaecological cancer, and the validity is not 
necessarily transferable to women with rectal cancer. There was no validated 
questionnaire for sexual function in rectal cancer patients at the time. However, 
because we aimed to use a questionnaire that covered vaginal problems often 
observed after pelvic RT, this questionnaire was considered an appropriate choice.  
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In modern radiotherapy, CT-based dose planning enables individually formed 
radiation fields with sparing of normal tissue. In our study there has been no effort to 
spare the female genitals because of the proximity to the CTV. It is not known 
whether modern radiation techniques like IMRT reduces the radiation-induced 
genital late effects and this need to be further studied. The feasibility and usefulness 
of measures like ovarian transposition or vaginal shielding in these patients is not 
clear, and the impact on sexual function has not been examined. Sexual dysfunction 
may be aggravated by radiation sensitizing chemotherapy; however, due to the 
limited number of patients this could not be evaluated in the present study. Future 
treatment may include combination chemotherapy with for instance irinotecan or 
oxaliplatin (which may affect peripheral nerves) or antibodies. The late toxicity of this 
treatment is not known and needs to be addressed in future studies.  
Prevention and treatment of the physical late effects from pelvic RT is an important 
goal for the individual patient with rectal cancer. On a general basis a Cochrane 
review concludes that there is sufficient evidence of  the benefits of vaginal dilators 
to prevent treatment-induced stenosis after pelvic radiotherapy and that such 
devices should be recommended [26]. The evidence for use of topical estrogens to 
prevent vaginal bleeding and dyspareunia is less clear and the benefit needs to be 
confirmed in larger studies [26]. Several non-randomized studies have shown 
promising results using hyperbaric oxygen in cases of radio necrotic injuries to the 
perineum and vagina [26]. Finally, consultations with a physician may be beneficial 
for the diagnosis and treatment of gynaecological side effects following pelvic RT for 
rectal cancer. 
18 
 
Sexual function and gynaecological problems are intimate subjects that are not 
easily brought up by all patients or physicians. Providing information about possible 
side-effects prior to treatment will make it easier for patients to identify and discuss 
these matters with physicians if symptoms or problems later develop.   
Conclusion 
There is an increased risk of dyspareunia and vaginal dryness in women following 
surgery combined with radiotherapy for rectal cancer than observed after surgery 
alone. Patients should receive information about the risk, and be encouraged to seek 
medical advice if needed.
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Table 1: Questions concerning vaginal problems in the SVQ  
11. Did you feel that your vagina was dry during intercourse?     
 
11a. If yes, has it bothered you? 
12. Have you had any pain during intercourse? 
12a. If yes, has it bothered you? 
13. Have you experienced bleeding during intercourse? 
13a. If yes, has it bothered you? 
14. Did you feel that intercourse was bothersome because your vagina felt too small? 
Answering categories: 
Not at all                 A little                  Quite a bit                  Very much 
     1                           2                               3                               4 
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Table 2. Patient characteristics of responding patients 
 
 
 RT+ group 
N=62 
RT- group 
N=110 
Age, median years, (range) 65 (42-79) 66 (50-79) 
Time since surgery, median years 
(range) 
4.3 (2.6-10.4) 4.7 (3.0-12.4) 
Resection type, n (%) 
   Low anterior resection 
   Abdominoperineal resection 
   Hartmann’s procedure 
 
30 (48) 
27 (44) 
5 (8) 
 
93 (85) 
16 (14) 
1 (1) 
Stoma present, n (%) 35 (57) 24 (22) 
Tumour distance from anal verge, 
median cm (range) 
7 (0-18) 10 (0-19) 
 (y)pT-stage, n (%) 
   T0/T1 
   T2 
   T3 
   T4 
 
6 (10) 
8 (13) 
42 (67) 
6 (10) 
 
16 (15) 
37 (34) 
53 (48) 
4(3) 
Chemotherapy, n (%) 39 (63) 2 (2) 
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 Table 3. Sexual function and vaginal changes scores in RT+ and RT- patients 
  
 
 RT+ group RT- group   
Scales   Range n (RT+/RT-) Mean (SD) Mean (SD) p* 
Intimacy   2-8 (58/102)      5.0 (1.7) 5.03 (1.5) 0.7 
Sexual interest  1-4 (59/102)      1.8 (0.8) 1.8 (0.9) 0.8 
Worries about sex life  2-11 (55/95) 5.3 (3.0) 4.8 (2.4) 0.6 
Vaginal changes**  4-16 (20/35) 9.1 (3.8) 6.8 (3.0) 0.02 
Vaginal bleeding during 
intercourse  
2-8 (20/34)       2.9 (2) 2.1 (2) 0.001 
Reduced vaginal dimension  1-4 (20/34) 2.1 (1.2) 1.2 (0.7) 0.001 
Sexual functioning***  3-12 (19/30) 8.4 (2.1) 9.2 (2.7) 0.15 
* Mann-Whitney U test 
** Lack of lubrication, dyspareunia, distress from lack of lubrication/ dyspareunia 
***Ability to complete intercourse, orgasm, relaxation after sex 
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Table 4: Odds ratio (OR) of sexual dysfunction and vaginal problems in RT+ patients 
compared to RT- patients, adjusted for age and the presence of stoma. 
 RT+ RT- OR p CI 
Sexual interest (1)                                  44/15 78/24 1.2 0.5 0.5-2.8 
Lack of lubrication (2)                              10/10 8/26 3.5 0.04 1.03-12.1 
Dyspareunia (2)                                          7/13 4/32 4.5 0.04 1.1-18.6 
Reduced vaginal dimension (2)                  7/13 2/32 8.9 0.01 1.6-50.3 
Able to complete intercourse (3)                   7/11 5/21 2.3 0.26 0.5-9.5 
Reach orgasm (3)                                        9/10 9/23 2.5 0.1 0.7-8.8 
1= no- low/ quite a bit- very much, 2= quite a bit- very much/ not at all- a little    
3= not at all- a little/ quite a bit- very much 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix$  

Senfølger etter behandling av kreft i endetarmen
1.Pasientnr:
Fødselsår:
Intervjuskjema
1.Mann
2.Kvinne
2.Kjønn:
3.Er du i arbeide?
1.Ja
2.Nei, sykemeldt
3.Nei, pensjonist
4.Nei, uføretrygdet
5.Nei, arbeidsløs
Hvilket år? Diagnose?
4. Har du eller har du hatt annen kreftsykdom i bekkenet  (colon/tykktarmskreft,
    prostatakreft, underlivskreft eller blærekreft)?
1.Nei
2.Ja , i tilfelle hva?
5. Hadde du blitt operert i magen før du ble operert for endetarmskreft?
1.Nei
2.Ja , operert for?
6. Har du noen av følgende sykdommer?
Sukkersyke, siden
Chrons sykdom, ulcerøs colitt, siden
Slitasjegikt i hoften (hofteleddsartrose), siden
Høyt blodtrykk, siden
årstall
årstall
årstall
årstall
7. Fikk du cellegift i forbindelse med behandlingen av endetarmskreften?
1.Nei
2.Ja
1
18614
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2Pasientnr:
9. Har du blitt behandlet for noen av følgende tilstander etter at du ble operert
    eller strålebehandlet for endetarmskreft?
Ja, forsnevring på tarmen/tarmslyng
Hvis ja, ble du operert? 1.Nei 2.Ja
Ja, fistel
Ja, hoftebrudd/lårhalsbrudd
Ja, hjerteinfarkt
Ja, hjerneslag
10. Hvis ja, har du vært innlagt på sykehus i forbindelse med behandlingen?
1.Nei
2.Ja
(Hvis nei, gå til spørsmål 13).
11. Ved hvilket sykehus var du innlagt?
12. Når var du innlagt? (Hvilket år)?
13. Bruker du noen medisiner?
1.Nei
2.Ja
(Hvis nei, gå til spørsmål 15).
8. Fikk du strålebehandling i forbindelse med behandlingen av endetarmskreft?
1.Nei
2.Ja, før operasjonen
3.Ja, etter operasjonen
4.Ja, både før og etter
år
år
sykehus
sykehus
operasjonen
år sykehus
18614
3Pasientnr:
1.Nei.
2.Ja, tidligere.
3.Ja, får nå.
15. Har du fått vitamin B12-sprøyter?
De neste spørsmålene vil handle om avføringsplager.
Vi er interessert i hvordan avføringen har vært den siste måneden.
16. Har du utlagt tarm (stomi)?
1.Nei
2.Ja
(Hvis nei, gå videre til spørsmål 18)
17. Hvor mange ganger i døgnet må du skifte posen?
1. 0-1 pr.dag
2. 2-4 pr. dag
3. 5-8 pr. dag
4. >8 pr. dag
5. Ukontrollert diare
18. Hvor mange ganger per døgn har du avføring?
1. 0-1 pr.dag
2. 2-4 pr. dag
3. 5-8 pr. dag
4. >8 pr. dag
5. Ukontrollert diare
14. Hvilke medisiner bruker du?
1
2
3
4
5
6
7
8
9
10
År:
Begynte år:
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20. Lider du av forstoppelse?
1.Nei
2.Har avføring 3-4 ganger pr. uke
3.Har avføring < 2 ganger pr. uke
4.Har < 1 avføring pr. uke
5.Har ikke hatt avføring på 10 dager
(Hvis nei, gå videre til spørsmål 22)
19. Hvilken konsistens har avføringen din?
1.Hard, knollete
2.Normal,myk
3.Litt løs
4.Løs
5.Slimete,vanntynn
21. Har du endret kosten eller bruker du regelmessig medisiner på grunn av forstoppelse?
Nei
Ja, lagt om kosten
Ja, bruker medisiner Hvilke? 1
2
3
4
5
22. Har du endret kosten eller bruker du regelmessig medisiner på grunn av diare?
Nei, aldri (Hvis nei, gå videre til spørsmål 24)
Ja, har lagt om kosten
Ja, Loperamid(Imodium) eller andre ikke-narkotiske stoffer
Ja, opiumsdråper eller andre narkotiske midler
23. Hvor ofte tar du medisiner på grunn av diare?
1.Nei, aldri
2.Sjelden, < 2 ganger pr. uke
3.Jevnlig, > 2 ganger pr. uke
4.Ofte, > 2 ganger pr. dag
5.Operasjon på grunn av diare
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24. Har du lekkasje av avføring hvis den er fast?
1.Aldri
2.Sjelden (en gang eller sjeldnere pr. måned)
3.Noen ganger
4.Ukentlig
5.Daglig
(mer enn en gang pr. måned, men sjeldnere enn en gang pr. uke)
25. Har du lekkasje av avføring hvis den er løs?
1.Aldri
2.Sjelden (en gang eller sjeldnere pr. måned)
3.Noen ganger
4.Ukentlig
5.Daglig
(mer enn en gang pr. måned, men sjeldnere enn en gang pr. uke)
(dersom aldri både på spørsmål 24 og 25, gå videre til spørsmål 29)
1.Om dagen
2.Om natten
3.Både dag og natt
26. Når på døgnet har du hatt lekkasje av avføring?
27. Har du måttet bruke noen form for sanitetsbind/bleie på grann av avføringslekkasje?
1.Nei
2.Ja
28. Medfører avføringslekkasje begrensinger i dagliglivets aktiviteter
      (som f.eks. jobb, fritidsaktiviteter eller husarbeide?
1.Aldri
2.Sjelden (en gang eller sjeldnere pr. måned)
3.Noen ganger
4.Ukentlig
5.Daglig
(mer enn en gang pr. måned, men sjeldnere enn en gang pr. uke)
29. Har du problemer med å holde på luft (flatulens)?
1.Aldri
2.Sjelden (en gang eller sjeldnere pr. måned)
3.Noen ganger
4.Ukentlig
5.Daglig
Hvis stomi, gå videre til spørsmål 33.
(mer enn en gang pr. måned, men sjeldnere enn en gang pr. uke)
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30. Hvor lenge kan du holde avføringen hvis det ikke er toalett i nærheten?
1.15 minutter eller lengre
2.Mindre enn 15 minutter
1.Nei
2.Ja, må benytte spesiell diett
3.Ja, har blitt dilatert/utvidet for dette på sykehus
4.Ja, må jevnlig til dilatasjon/utvidelse på sykehus for dette
31. Har du forsnevring på endetarmen?
32. Har du krampelignende smerter i endetarmen i forbindelse med avføring?
1.Aldri
2.Sjelden (en gang eller sjeldnere pr. måned)
3.Noen ganger
4.Ukentlig
5.Daglig
33. Har du smerter fra endetarmen/setet?
1.Aldri
2.Sjelden (en gang eller sjeldnere pr. måned)
3.Noen ganger
4.Ukentlig
5.Daglig
1.Aldri
2.Sjelden (en gang eller sjeldnere pr. måned)
3.Noen ganger
4.Ukentlig
5.Daglig
34. Har du magesmerter?
(Hvis aldri, gå videre til spørsmål 37)
(mer enn en gang pr. måned, men sjeldnere enn en gang pr. uke)
(mer enn en gang pr. måned, men sjeldnere enn en gang pr. uke)
35. Tar du smertestillende medisiner på grunn av smerter fra mage eller endetarm?
1.Aldri
2.En gang i blant
3.Daglig
4.Er operert på grunn av smertene
(Hvis aldri, gå til spørsmål 37)
(mer enn en gang pr. måned, men sjeldnere enn en gang pr. uke)
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36. Hvilke smertestillende medisiner bruker du mot disse smertene?
1
2
3
37. Har du slim i avføringen?
1.Aldri
2.Sjelden (en gang eller sjeldnere pr. måned)
3.Noen ganger
4.Ukentlig
5.Daglig
(mer enn en gang pr. måned, men sjeldnere enn en gang pr. uke)
38. Har du blod i avføringen eller blod fra endetarmen?
1.Aldri
2.Påvist ved prøve hos legen(hemo fec)
3.> 2 ganger pr. uke
4.Daglig
5.Større blødning
(Hvis aldri, gå til spørsmål 40)
39. Får du behandling på grunn av blod i avføringen?
1.Nei
2.Jerntabletter
3.Har fått enkelte blodoverføringer
4.Får ofte blodoverføring
5.Er blitt operert for dette
40. Medfører tarmfunksjonen din begrensinger i dagliglivets aktiviteter
      (som f.eks. jobb, fritidsaktiviteter eller husarbeide)?
1.Store begrensinger
2.Noen begrensinger
3.Ingen begrensinger
41. Medfører tarmfunksjonen  begrensinger i ditt sosiale liv?
1.Store begrensinger
2.Noen begrensinger
3.Ingen begrensinger
18614
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42. Hvor tilfreds er du med tarmfunksjonen din?
1.Svært fornøyd
2.Noe fornøyd
3.Nøytral
4.Noe misfornøyd
5.Svært misfornøyd
De neste spørsmålene vil handle om vannlatingsplager.
Vi er interessert i hvordan vannlatingen har vært den siste måneden.
43. Hvor lang tid er det mellom hver gang du må late vannet?
1.> 4 timer
2. 3-4 timer
3. 2-3 timer
4. 1-2 timer
5.Hver time
44. Har du dårlig trykk på urinstrålen?
1.Aldri
2. Månedlig
3. Ukentlig
4. Hver dag, bruker ikke kateter
5.Hver dag, bruker kateter
45. Har du svie eller smerter ved vannlating?
1.Aldri
2.Sjelden (en gang eller sjeldnere pr. måned)
3.Noen ganger
4.Ukentlig
5.Daglig
(mer enn en gang pr. måned, men sjeldnere enn en gang pr. uke)
46. Bruker du smertestillende mot disse plagene?
1.Aldri
2.En gang i blant
3.Daglig
4.Er operert på grunn av smertene
(Hvis aldri, gå til spørsmål 48)
(Hvis aldri, gå til spørsmål 48)
18614
47. Hvilke smertestillende medisiner bruker du mot vannlatingsplager?
1
2
3
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48. Har du blod i urinen?
1.Aldri
2.Sjelden (en gang eller sjeldnere pr. måned)
3.Noen ganger
4.Ukentlig
5.Daglig
(mer enn en gang pr. måned, men sjeldnere enn en gang pr. uke)
(Hvis aldri, gå til spørsmål 50)
49. Får du behandling på grunn av blod i urinen?
1.Nei
2.Jerntabletter
3.Har fått enkelte blodoverføringer eller brenning (kauterisasjon)
4.Får ofte blodoverføring eller brenning (kauterisasjon)
5.Er blitt operert på grunn av blødning
50. Har du hatt ufrivillig vannlating/lekkasje?
1.Nei
2.< Ukentlige episoder
3.< Daglige episoder
4.< 2 bind pr. dag
5.Konstant
(Hvis nei, gå til spørsmål 52)
51. Bruker du bind/bleie på grunn av urinlekkasje?
1.Aldri
2.Sjelden (en gang eller sjeldnere pr. måned)
3.Noen ganger
4.Daglig bruk av bind/bleie eller selvkateterisering
5.Har permanent kateter
(mer enn en gang pr. måned, men sjeldnere enn en gang pr. uke)
18614
Pasientnr:
10
52. Medfører vannlatingsmønsteret ditt begrensinger i dagliglivets
      aktiviteter (f.eks. jobb, fritidsaktiviteter eller husarbeide)?
1.Store begrensinger
2.Noen begrensinger
3.Ingen begrensinger
53. Medfører vannlatingsmønsteret begrensinger i ditt sosiale liv?
1.Store begrensinger
2.Noen begrensinger
3.Ingen begrensinger
54. Hvor tilfreds er du med vannlatingsfunksjonen din?
1.Svært fornøyd
2.Noe fornøyd
3.Nøytral
4.Noe misfornøyd
5.Svært misfornøyd
De siste spørsmålene vil handle om hoftesmerter og røyking.
55. Har du smerter i hoften som du ikke hadde før behandlingen for endetarmskreft?
1.Aldri
2.Sjelden (en gang eller sjeldnere pr. måned)
3.Noen ganger
4.Ukentlig
5.Daglig
(mer enn en gang pr. måned, men sjeldnere enn en gang pr. uke)
(Hvis nei, gå til spørsmål 58)
56. Bruker du medisiner på grunn av hoftesmertene?
1.Aldri
2.En gang i blant
3.Daglig
4.Er operert på grunn av smertene
(Hvis aldri, gå til spørsmål 58)
18614
11
Pasientnr:
57. Hvilke  medisiner bruker du ?
3
2
1
58. Har du noen gang røkt?
1.Nei
2.Ja
(Hvis nei, gå til spørsmål 62)
59. Røyker du nå?
1.Nei, sluttet
2.Ja
Årstall?
60. Hvor mange sigaretter har du røkt daglig?  Ca.
61. I hvor mange år har du røkt?  Ca.
62. Har du hatt andre problemer eller plager enn du har nevnt her, som du
      knytter til operasjonen for endetarmskreft eller strålebehandlingen?
Takk for hjelpen!
1.Nei, sluttet
2.Ja
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NORWEGIAN
EORTC QLQ-C30 (version 3.0.)
Vi er interessert i forhold vedrørende deg og din helse. Vær så vennlig å besvare hvert spørsmål ved å sette
en ring rundt det tallet som best beskriver din tilstand. Det er ingen "riktige" eller "gale" svar. Alle
opplysningene vil bli behandlet konfidensielt.
Ditt navns forbokstaver: 
Født (dag, mnd, år): 
Dato (dag, mnd, år): 31
Ikke i det Svært
hele tatt Litt Endel mye
1. Har du vanskeligheter med å utføre anstrengende
aktiviteter, slik som å bære en tung handlekurv
eller en koffert? 1 2 3 4
2. Har du vanskeligheter med å gå en lang tur? 1 2 3 4
3. Har du vanskeligheter med å gå en kort tur utendørs? 1 2 3 4
4. Er du nødt til å ligge til sengs eller sitte i en stol
i løpet av dagen? 1 2 3 4
5. Trenger du hjelp til å spise, kle på deg, vaske deg
eller gå på toalettet? 1 2 3 4
I løpet av den siste uka: Ikke i det Svært
hele tatt Litt Endel mye
6. Har du hatt redusert evne til å arbeide eller
utføre andre daglige aktiviteter? 1 2 3 4
7. Har du hatt redusert evne til å utføre dine
hobbyer eller andre fritidsaktiviteter? 1 2 3 4
8. Har du vært tung i pusten? 1 2 3 4
9. Har du hatt smerter? 1 2 3 4
10. Har du hatt behov for å hvile? 1 2 3 4
11. Har du hatt søvnproblemer? 1 2 3 4
12. Har du følt deg slapp? 1 2 3 4
13. Har du hatt dårlig matlyst? 1 2 3 4
14. Har du vært kvalm? 1 2 3 4
Bla om til neste side
Appendix B
NORWEGIAN
I løpet av den siste uka: Ikke i det Svært
hele tatt Litt Endel mye
15. Har du kastet opp? 1 2 3 4
16. Har du hatt treg mage? 1 2 3 4
17. Har du hatt løs mage? 1 2 3 4
18. Har du følt deg trett? 1 2 3 4
19. Har smerter påvirket dine daglige aktiviteter? 1 2 3 4
20. Har du hatt problemer med å konsentrere deg,
f.eks. med å lese en avis eller se på TV? 1 2 3 4
21. Har du følt deg anspent? 1 2 3 4
22. Har du vært engstelig? 1 2 3 4
23. Har du følt deg irritabel? 1 2 3 4
24. Har du følt deg deprimert? 1 2 3 4
25. Har du hatt problemer med å huske ting? 1 2 3 4
26. Har din fysiske tilstand eller medisinske behandling
påvirket ditt familieliv? 1 2 3 4
27. Har din fysiske tilstand eller medisinske behandling
påvirket dine sosiale aktiviteter? 1 2 3 4
28. Har din fysiske tilstand eller medisinske behandling
gitt deg økonomiske problemer? 1 2 3 4
Som svar på de neste spørsmålene sett en ring rundt det tallet fra 1 til 7
som best beskriver din tilstand
29. Hvordan har din helse vært i løpet av den siste uka?
1 2 3 4 5 6 7
Svært  Helt
dårlig  utmerket
30.Hvordan har livskvaliteten din vært i løpet av den siste uka?
1 2 3 4 5 6 7
Svært  Helt
dårlig  utmerket
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Senfølger etter behandling av kreft i endetarmen
Spørreskjema om seksualfunksjon, menn Pasientnr:
Fødselsår:
Følgende spørsmål gjelder hvordan dine ereksjonsproblemer har virket inn på sexlivet ditt
i løpet av de siste 4 ukene.  Vennligst svar på spørsmålene så oppriktig og klart som mulig.
Vennligst svar på hvert av spørsmålene ved å merke av èn rute med et kryss      .
Hvis du er usikker på hva du skal svare, svar så godt du kan.
x
Følgende definisjoner gjelder når du svarer på disse spørsmålene:
* Samleie
 Defineres som inntrenging (innføring) i partnerens skjede.
** Seksuell aktivitet
 Omfatter samleie, kjærtegn, forspill og onani.
*** Sæduttømming
 Defineres som uttømming av sæd fra penis (eller fornemmelsen av dette).
**** Seksuell stimulering
 Omfatter slike situasjoner som erotisk lek med en partner, det å se på erotiske bilder, osv.
1. I løpet av de siste 4 ukene  hvor ofte var du i stand til å få ereksjon under seksuell aktivitet ** ?
Vennligst kryss av i bare èn rute.
1.Ingen seksuell aktivitet
2.Nesten alltid eller alltid
3.De fleste gangene (mye mer enn halvparten av gangene)
4.Iblant (omtrent halvparten av gangene)
5.Noen få ganger (mye mindre enn halvparten av gangene)
6.Nesten aldri eller aldri
2. I løpet av de siste 4 ukene  når fikk du ereksjon med seksuell stimulering ****,
   hvor ofte var ereksjonene stive nok til inntrenging?
Vennligst kryss av i bare èn rute.
1.Ingen seksuell stimulering
2.Nesten alltid eller alltid
3.De fleste gangene (mye mer enn halvparten av gangene)
4.Iblant (omtrent halvparten av gangene)
5.Noen få ganger (mye mindre enn halvparten av gangene)
6.Nesten aldri eller aldri
1IIEFnor0.doc - IIEF Norwegian version
13085
Appendix C
Pasientnr:
2IIEFnor0.doc - IIEF Norwegian version
De 3 neste spørsmålene gjelder de ereksjonene du eventuelt har hatt under samleie *.
3. I løpet av de siste 4 ukene  når du forsøkte å ha samleie*, hvor ofte var du i stand til å
    trenge inn i partneren?
Vennligst kryss av i bare èn rute.
1.Har ikke forsøkt å ha samleie
2.Nesten alltid eller alltid
3.De fleste gangene (mye mer enn halvparten av gangene)
4.Iblant (omtrent halvparten av gangene)
5.Noen få ganger (mye mindre enn halvparten av gangene)
6.Nesten aldri eller aldri
4. I løpet av de siste 4 ukene  under samleie* hvor ofte var du i stand til å beholde ereksjonen
    etter inntrenging i partneren?
Vennligst kryss av i bare èn rute.
1.Har ikke forsøkt å ha samleie
2.Nesten alltid eller alltid
3.De fleste gangene (mye mer enn halvparten av gangene)
4.Iblant (omtrent halvparten av gangene)
5.Noen få ganger (mye mindre enn halvparten av gangene)
6.Nesten aldri eller aldri
5. I løpet av de siste 4 ukene  under samleie* hvor vanskelig var det å beholde ereksjonen
    til samleiet var fullført?
Vennligst kryss av i bare èn rute.
1.Har ikke forsøkt å ha samleie
2.Ekstremt vanskelig
3.Svært vanskelig
4.Vanskelig
5.Litt vanskelig
6.Ikke vanskelig
* Samleie: Defineres som inntrenging (innføring) i partnerens skjede.
** Seksuell aktivitet:  Omfatter samleie, kjærtegn, forspill og onani.
*** Sæduttømming:  Defineres som uttømming av sæd fra penis (eller fornemmelsen av dette).
**** Seksuell stimulering: Omfatter slike situasjoner som erotisk lek med en partner, det å se på erotiske bilder, osv.
13085
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* Samleie: Defineres som inntrenging (innføring) i partnerens skjede.
** Seksuell aktivitet:  Omfatter samleie, kjærtegn, forspill og onani.
*** Sæduttømming:  Defineres som uttømming av sæd fra penis (eller fornemmelsen av dette).
**** Seksuell stimulering: Omfatter slike situasjoner som erotisk lek med en partner, det å se på erotiske bilder, osv.
6. I løpet av de siste 4 ukene  hvor mange ganger har du forsøkt å ha samleie*?
Vennligst kryss av i bare èn rute.
1.Ingen forsøk
2.1-2 forsøk
3.3-4 forsøk
4.5-6 forsøk
5.7-10 forsøk
6.11 eller flere forsøk
7. I løpet av de siste 4 ukene  når du forsøkte å ha samleie*, hvor ofte var det
    tilfredsstillende for deg?
Vennligst kryss av i bare èn rute.
1.Har ikke forsøkt å ha samleie
2.Nesten alltid eller alltid
3.De fleste gangene (mye mer enn halvparten av gangene)
4.Iblant (omtrent halvparten av gangene)
5.Noen få ganger (mye mindre enn halvparten av gangene)
6.Nesten aldri eller aldri
8. I løpet av de siste 4 ukene  hvor mye glede har du hatt av samleie*?
Vennligst kryss av i bare èn rute.
1.Ikke samleie
2.Svært mye glede
3.Mye glede
4.En del glede
5.Lite glede
6.Ingen glede
13085
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Defineres som inntrenging (innføring) i partnerens skjede.
 Omfatter samleie, kjærtegn, forspill og onani.
 Defineres som uttømming av sæd fra penis (eller fornemmelsen av dette).
Omfatter slike situasjoner som erotisk lek med en partner, det å se på erotiske bilder, osv.
* Samleie:
** Seksuell aktivitet:
*** Sæduttømming:
**** Seksuell stimulering:
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9. I løpet av de siste 4 ukene  under seksuell stimulering ****,  eller samleie *,
    hvor ofte hadde du sæduttømming?
Vennligst kryss av i bare èn rute.
1.Ingen seksuell stimulering eller samleie
2.Nesten alltid eller alltid
3.De fleste gangene (mye mer enn halvparten av gangene)
4.Iblant (omtrent halvparten av gangene)
5.Noen få ganger (mye mindre enn halvparten av gangene)
6.Nesten aldri eller aldri
10. I løpet av de siste 4 ukene  under seksuell stimulering ****, eller samleie *,
    hvor ofte hadde du følelesen av orgasme med eller uten sæduttømming *** ?
Vennligst kryss av i bare èn rute.
1.Ingen seksuell stimulering eller samleie
2.Nesten alltid eller alltid
3.De fleste gangene (mye mer enn halvparten av gangene)
4.Iblant (omtrent halvparten av gangene)
5.Noen få ganger (mye mindre enn halvparten av gangene)
6.Nesten aldri eller aldri
11. I løpet av de siste 4 ukene  under seksuell stimulering ****, eller samleie *,
    hvor ofte hadde du følelsen av orgasme, men  uten sæduttømming *** ?
Vennligst kryss av i bare èn rute.
1.Ingen seksuell stimulering eller samleie
2.Nesten alltid eller alltid
3.De fleste gangene (mye mer enn halvparten av gangene)
4.Iblant (omtrent halvparten av gangene)
5.Noen få ganger (mye mindre enn halvparten av gangene)
6.Nesten aldri eller aldri
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* Samleie:
** Seksuell aktivitet:
*** Sæduttømming:
**** Seksuell stimulering:
Defineres som inntrenging (innføring) i partnerens skjede.
 Omfatter samleie, kjærtegn, forspill og onani.
 Defineres som uttømming av sæd fra penis (eller fornemmelsen av dette).
Omfatter slike situasjoner som erotisk lek med en partner, det å se på erotiske bilder, osv.
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De 2 neste spørsmålene gjelder seksuelt begjær. La oss definere seksuelt begjær som
en følelse som kan omfatte et ønske om å ha en seksuell opplevelse (f.eks. onani eller
samleie *), å tenke på sex eller å være frustrert over mangel på sex.
12. I løpet av de siste 4 ukene hvor ofte har du følt seksuelt begjær?
Vennligst kryss av i bare èn rute.
1.Nesten alltid eller alltid
2.Svært ofte (svært mye av tiden)
3.Av og til (en del av tiden)
4.Sjelden (litt av tiden)
5.Nesten aldri eller aldri
13. I løpet av de siste 4 ukene hvordan vil du beskrive nivået på ditt  seksuelle begjær?
Vennligst kryss av i bare èn rute.
1.Svært høyt
2.Høyt
3.Middels
4.Lavt
5.Svært lavt eller intet
14. I løpet av de siste 4 ukene hvor tilfreds har du vært med sexlivet ditt alt i alt?
Vennligst kryss av i bare èn rute.
1.Svært tilfreds
2.Ganske tilfreds
3.Omtrent like mye tilfreds som utilfreds
4.Ganske utilfreds
5.Svært utilfreds
13085
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* Samleie:
** Seksuell aktivitet:
*** Sæduttømming:
**** Seksuell stimulering:
Defineres som inntrenging (innføring) i partnerens skjede.
 Omfatter samleie, kjærtegn, forspill og onani.
 Defineres som uttømming av sæd fra penis (eller fornemmelsen av dette).
Omfatter slike situasjoner som erotisk lek med en partner, det å se på erotiske bilder, osv.
15. I løpet av de siste 4 ukene hvor tilfreds har du vært med ditt seksuelle forhold
      til din partner?
Vennligst kryss av i bare èn rute.
1.Svært tilfreds
2.Ganske tilfreds
3.Omtrent like mye tilfreds som utilfreds
4.Ganske utilfreds
5.Svært utilfreds
16. I løpet av de siste 4 ukene hvordan vil du beskrive din tiltro til å kunne få
      og beholde en ereksjon
Vennligst kryss av i bare èn rute.
1.Svært stor
2.Stor
3.Middels
4.Liten
5.Svært liten
17. I løpet av de siste 4 ukene har du brukt medikamenter eller hjelpemidler
      (tabletter,  sprøyter, implantat) for å oppnå ereksjon?
1. Nei 2. Ja Hvilke?
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1. Har du hatt ønske om nær fysisk kontakt
      (klem og kyss)?
2. Har du hatt nær fysisk kontakt med dine nærmeste?
3. Har du hatt ønske om seksuelt samvær?
4. Har du en partner?
      (Hvis ikke, vennligst fortsett til spørsmål 8).
5. Har din partner hatt ønske om seksuelt samvær?
6. Har dere hatt seksuelt samvær?
      (Hvis du har svart "nei" til dette spørsmålet,
        vennligst fortsett til spørsmål 8).
7. Hadde din partner problemer med å
      få ereksjon?
8. Har ditt seksualliv/mangel på seksualliv
      gitt deg bekymringer?
Nei
Ja, 1-2
ganger i
måneden
Ikke i det
hele tatt
Litt En del Svært
mye
Bla om til neste side
Pasientnr:
Fødselsår:
Senfølger etter behandling av kreft i endetarmen
Spørreskjema om seksualfunksjon, kvinner
Fysisk kontakt og seksuelt samvær kan være en viktig del av mange menneskers liv.
Personer som får sykdommer som involverer underlivet, kan oppleve endringer i seksuallivet.
De følgende spørsmål handler om dette.
Svarene vil bli behandlet streng fortrolig.
Vennligst svar på alle spørsmålene selv ved å sette et kryss i den ruten som best beskriver din tilstand.
Del 1.
I løpet av den siste måneden:
Ja Nei
Ja, 3-4
ganger i
måneden
Ja, 1-2
ganger i
uken
Ja, mer enn
2 ganger i
uken
Ikke i det
hele tatt
Litt En del Svært
mye
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11.  Følte du at skjeden var tørr ved samleie?
11a. Hvis ja, har det vært et problem for deg?
12.  Har du hatt smerter ved samleie?
12a. Hvis ja, har det vært et problem for deg?
13.   Har du hatt blødning ved samleiet?
13a. Hvis ja, har det vært et problem for deg?
Som svar på de neste 2 spørsmålene, sett et kryss i den boksen fra 1 til 7 som best beskriver din
tilstand.
9. Hvor fornøyd eller misfornøyd er du med ditt seksualliv/mangel på seksualliv?
10. Hvor fornøyd eller misfornøyd har du vært med utseendet ditt?
1 2 3 4 5 6 7
1 2 3 4 5 6 7
Svært misfornøyd    Svært fornøyd
utmerket
Svært misfornøyd              Svært fornøyd
Vennligst fortsett med del 2. av spørreskjemaet hvis du har vært seksuelt aktiv i løpet av den siste  måneden.
 Hvis du ikke har vært seksuelt aktiv skal du ikke svare på flere spørsmål.
Del 2.
I løpet av den siste måneden:
14.   Følte du at skjedens størrelse var problematisk
        ved samleie fordi den var for liten?
15.   Var dere i stand til å gjennomføre samleiet?
16.   Har du hatt orgasme?
17.   Følte du deg avslappet etter det seksuelle samværet?
Seksualfunksjon kvinner s.2
Pasientnr:
Ikke i det
hele tatt
Litt En del Svært
mye
18. Bruker du krem/salve/stikkpiller på grunn av tørrhet i skjeden? 1. Nei 2. Ja
19. I tilfelle hva? a b
20. Har du brukt glasstav mot tranghet i skjeden? 1. Nei 2. Ja
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